Prof. Dr. Barbara Seliger

Magnifier Icon Suche

Im Jahr 2003 habe ich als Direktorin die Leitung des Instituts für Medizinische Immunologie übernommen. Anfang 2011 wurde das Institut von der internationalen Vereinigung der klinisch-immunologischen Gesellschaften (Federation of Clinical Immunology Societies) zu einem „Center of Excellence“ ernannt. Damit zählt das Institut zu den führenden Einrichtungen auf diesem Gebiet weltweit.

Im Rahmen der Grundlagenforschung befasse ich mich schwerpunktmäßig mit tumorimmunologischen und tumorbiologischen Fragestellungen, sowie mit der Identifizierung von Kandidatenbiomarkern, die potentiell als diagnostische, prognostische Marker, für die Überprüfung des Ansprechens auf Therapiemaßnahmen oder gar als therapeutisch nutzbare Zielstrukturen einsetzbar sind.

Im translationalen Forschungsbereich führe ich verschiedene, auch internationale, Forschungs- und Immunomonitoringprojekte durch, die partiell eng mit klinischen Studien verbunden sind. Hierbei stehen vor allem die Wirkung, sowie die Entwicklung von Resistenzen gegen zielgerichtete Therapeutika und ihr Effekt auf Immunzellsubpopulationen im Fokus der laufenden Arbeiten.

  • Durchflusszytometrische Diagnostik
  • Immundefektdiagnostik
  • Leukozytentypisierung der Bronchoalveolären Lavageflüssigkeit (BALF)
  • Hämatologische Zelltypisierungen
  • Tumorimmunologie (Immune escape, Tumormikromilieu, Immunsubpopulationen)

  • Tumorbiologie (Onkogene, Signaltransduktion, Transkriptionsfaktoren)

  • Immun- und zielgerichtete Therapie

  • Identifizierung von Biomarkern

  • Entwicklung standardisierter Immunüberwachung/Immunoscore

Das Institut für Medizinische Immunologie hat zahlreiche nationale und internationale Kollaborationen. Diese erfolgen zum einen im Rahmen von internationalen Netzwerken, wie die Society for Immunology and Cellular Therapy (SITC), Association for Cancer Immunotherapy (CIMT), FOCIS Center of Excellence und europäische bzw. multinationale Forschungsprojekte, wie z.B. die EU-Verbundprojekte EUCAAD und ENTIRE und die German-Israelian Foundation (GIF).

Al-Samadi, Ahmed(University of Helsinki, Department of Oral and Maxillofacial Diseases, Helsinki, Finland)

Ascierto, Paolo (Unit of Medical Oncology and Innovative Therapies, Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy)

Balko, Justin (Dept. of Medicine and Pathology, Microbiology, and Immunology, Cancer Biology Program and Breast Cancer Research Program, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, Texas, USA)

Carbone, Ennio (University of Catanzaro Magna Graecia, Medical School, Tumorimmunology Laboratory, Biological Building, University Campus"S Venuta", Catanzaro, Italy)

Carosella, Edgardo (CEA-SRHI, Hopital Saint-Louis, Institut Universitaire d'Hématologie, Paris, France)

Ferrone, Soldano (Division of Surgical Oncology, Dept. of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA)

Fox, Bernard (Providence Portland Medical Center, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Laboratory of Molecular & Tumor Immunology, Portland, Oregon, USA)

Galluzzi, Lorenzo (Weill Medical College of Cornell University, Dept. of Radiation Oncology, New York, USA)

Galon, Jérôme (INSERM - UMRS1138 - Laboratory of Integrative Cancer Immunology, Paris, France)

Garrido, Federico (Dept. Analisis Clinicos & Inmunologia, Hospital Universitario Virgen de las Nieves, Granada, Spain)

Ibrahim, Rami (Parker Institute for Cancer Immunotherapy, San Francisco, USA)

Khleif, Samir N. (Jeannie and Tony Loop Immuno-Oncology Center, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C., USA)

Kiessling, Rolf (Cancer Center Karolinska, Karolinska Hospital, Immune and Genetherapy Laboratory (IGT), Stockholm, Sweden)

Lindsley, Erika (Adaptive Biotechnologies Corp., Seattle, USA)

Maio, Michele (Division of Medical Oncology and Immunotherapy, Dept. of Oncology, University Hospital of Siena, Siena, Italy)

Mandelboim, Ofer (Dept. of Immunology, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel)

Marincola, Francesco (Refuge Biotechnologies Inc., Menlo Park, California, USA)

Ogino, Shuji (Department of Epidemiology-Harvard T.H. Chan School of Public Health, Department of Pathology-Brigham and Women’s Hospital, Department of Oncologic Pathology-Dana-Farber Cancer Institute, Boston, USA)

Rivoltini, Licia (Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milano, Italy)

Abken, Hinrich (Universitätsklinikum, Klinik I für Innere Medizin, Tumorgenetik und Zellbiologie, Zentrum für Molekulare Medizin Köln (ZMMK), Köln)

Bachmann, Michael (Helmholtz-Zentrum Dresden-Rossendorf, Institut für Radiopharmazeutische Krebsforschung, Leipzig)

Budczies, Jan (Universitätsklinikum Heidelberg, Pathologisches Institut, Allgemeine Pathologie und pathologische Anatomie, Heidelberg)

Denkert, Carsten (Universitätsklinikum Marburg, Institut für Pathologie, Marburg)

Dietz, Andreas (Universitätsklinikum Leipzig, Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Leipzig)

Eichmüller, Stefan (GMP & T Cell Therapy, DKFZ, Heidelberg)

Fasching, Peter (Universitätsklinikum Erlangen, Frauenklinik, Erlangen)

Giese, Thomas (Universitätsklinikum Heidelberg, Institut für Immunologie)

Grünwald, Viktor (Universitätsklinikum Essen, Klinik und Poliklinik für Urologie, Kinderurologie und Uroonkologie, Essen)

Hartmann, Arndt (Universitätsklinikum Erlangen, Institut für Pathologie, Erlangen)

Jonigk, Danny (Medizinische Hochschule Hannover, Institut für Pathologie, Hannover)

Karn, Thomas (Universitätsklinikum Frankfurt, Klinik für Frauenheilkunde und Geburtshilfe, Labor für translationale Forschung, Frankfurt am Main)

Köhl, Ulrike (Fraunhofer-Institut für Zelltherapie und Immunologie IZI, Leipzig und Institut für Klinische Immunologie an der Universität und dem Universitätsklinikum Leipzig)

Kunz, Manfred (Universitätsklinikum Leipzig, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Leipzig)

Loibl, Sibylle (German Breast Group Forschungs GmbH, Neu-Isenburg)

Reiche, Kristin (Fraunhofer-IZI, Abteilung Diagnostik, AG Bioinformatik, Leipzig)

Schmitz, Marc (Technische Universität Dresden, Institut für Immunologie, Dresden)

Schwab, Matthias (Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart und Abteilung für Klinische Pharmakologie, Institut experimentelle und klinische Pharmakologie und Toxikologie, Universitätsklinikum Tübingen)

Staehler, Michael (Institut für Urologie, Ludwig-Maximilians-Universität, Klinikum Großhadern, München) 

Stentzinger, Albrecht (Universitätsklinikum Heidelberg, Pathologisches Institut, Allgemeine Pathologie und pathologische Anatomie, Heidelberg)

Strick, Reiner (Universitätsklinikum Erlangen, Frauenklinik, Erlangen)

Weber, Karsten (German Breast Group Forschungs GmbH, Neu-Isenburg)

Wild, Peter (SIP-Dr. Senckenbergisches Instituts für Pathologie, Frankfurt am Main)

Wunderle, Marius (Universitätsklinikum Erlangen, Frauenklinik, Erlangen)

Gekle, Michael

Hüttelmaier, Stefan

Kantelhardt, Eva

Kessler, Sonja

Michl, Patrick

Otto, Sven

Simm, Andreas

Vordermark, Dirk

Wessjohann, Ludger

Wickenhauser, Claudia

seit 2011 Direktorin des FOCIS Centers of Excellenz in Halle, Deutschland
seit 2003 Lehrstuhlinhaberin (C4) für Immunologie, Direktorin des Institutes für Medizinische Immunologie, Martin-Luther-Universität Halle-Wittenberg
2000 Gastprofessorin, Karolinska Institut Stockholm, Schweden
1999 Gastprofessorin, Weizman Institut in Rehovot, Israel
1993 – 2003 C3-Professur und Leitung der Pathopysiologischen Forschung, Johannes-Gutenberg-Universität Mainz, Deutschland
1990 – 1993 Assistenzprofessur, Ludwig Institut für Krebsforschung Karolinska, Stockholm, Schweden
2016 Hugo Junkers Preis für das innovativste Forschungsprojekt, Deutschland
2014 ARF2014 Award der Qatar Research Foundation, Doha, Qatar
2006 Award of the Union for International Cancer Controls (UICC) Genf, Schweiz
2005 AIO Award (Berlin)
1999 Eisenbach Fellowship (Weizman Institute, Rehovot, Israel)
1996 EMBO Fellowship (ETH Zürich, Schweiz)
1980-1984 Studienstiftung Deutschen Volkes
1979 DAAD Fellowship
1978 Bayer Research Fellowship
1969, 1970 Jugend forscht

Begutachtung von Forschungsanträgen/ -projekten/-verbünden

Nationale Forschungsprojekte (BMBF/KMU, DFG, SFB, Mildred Scheel Krebsforschung, Sander Stiftung, etc.), internationale Forschungsprojekte (AAI, AACR, Britische Krebsforschung, Holländische Krebsforschung, etc.)

Begutachtung von Publikationen für Zeitschriften

verschiedene Mitarbeiter des Institutes sind häufig Reviewer für Pubmed-gelistete Zeitschriften (Proteomics, International Journal of Cancer, PLoS One, Lancet, Cancer Research, Clinical Cancer Research, Journal National Cancer Institute, Molecular Cellular Proteomics, Cancer Immunology Immunotherapy, Nature Immunology, etc.). 

Mentoring-Programm

Jahrelange Aktivität in Mainz, Halle/Jena/Leipzig

  • Oncoimmunology
  • Proteomics
  • Journal of Translational Medicine

Buchbeiträge:

Heat Shock Proteins in Renal Cell Carcinoma, Derek Atkins, Rudolf Lichtenfels and Barbara Seliger; Karger (2005)

Identification of diagnostic biomarkers for tumors by proteome analysis in Methods, Cancers and Perspectives of Pre-symptomatic Tumor Diagnostics; Barbara Seliger, Karger (2005)

Phänotypisierung von Tumorzellen; Barbara Seliger, Karger (2005)

Biomarker discovery in renal cell carcinoma applying proteome-based studies in combination with serology; Barbara Seliger and Roland Kellner, Wiley (2006)

Humoral antigens in cancer: Serological identification methods, Part II: Proteomex and AMIDA; Olivier Gires und Barbara Seliger, CCG Molecular Oncology (2007)

Potential immune escape mechanisms of tumors: MHC class I molecules – enemies or friends; Barbara Seliger, Springer (2008)

Renal and urinary proteomics: Methods and Protocols; Barbara Seliger, Rudolf Lichtenfels, Maja Baumgaertner, Christian Recktenwald and Sven Dressler, Wiley (October 2009)

Tumor-associated antigens; Edited by Olivier Gires und Barbara Seliger, Wiley (2009)

PROTEOMEX Analysis of Renal Cell Carcinoma; Rudolf Lichtenfels und Barbara Seliger, Wiley (2009)

The non-classical antigens of HLA-G and HLA-E as diagnostic and prognostic biomarkers and as therapeutic targets in transplantation and tumors; Barbara Seliger, Clinical Transplants, Terasaki Foundation Laboratory, Los Angeles, California (2013)

B7-H Abnormalities in Melanoma and Clinical Relevance; Barbara Seliger, Springer (2013)

Role of the Non-classical HLA class I Antigens for Immune Escape; Barbara Seliger und Simon Jasinski-Bergner, Springer (2015)

The Role of Immune Modulatory MicroRNAs in Tumors; Barbara Seliger, Anne Meinhardt und Dörte Falke, InTech (2016)

Rediscovering an old story: HLA class I alterations and immune escape of tumors in the context of immunotherapies; Barbara Seliger, Infinite Science Publishing (2018)

 

Zeitschriftenbeiträge:

Molekulare Diagnostik bei soliden Tumoren; Frank Bartel, Udo Siebolts, Claudia Wickenhauser, Barbara Seliger; BioSpektrum, Ausgabe 7/2014, Springer (2014)

Die Zukunft der Immuntherapie in Tumoren. Zeitschrift "Leben"; Jahrgang 16, Ausgabe 01/2016, Krebsgesellschaft Sachsen-Anhalt, ISSN 1864-7804

Expression and clinical significance of SARS-CoV-2 human targets in neoplastic and non-neoplastic lung tissues. Subbarayan K, Ulagappan K, Wickenhauser C, Seliger B. Curr Cancer Drug Targets. 2020 Dec 7. doi: 10.2174/1568009620666201207145019. Online ahead of print. PMID: 33292131

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Weber K, Seliger B. J Immunother Cancer. 2020 Nov;8(2):e001261. doi: 10.1136/jitc-2020-001261. PMID: 33199511

Cumulative suppressive index as a predictor of relapse free survival and overall survival in Human Papilloma Virus-negative oral squamous cell carcinomas with negative resection margins. Hum L, Bethmann D, Feng Z, Chang SC, Eckert A, Ballesteros-Merino C, Keschke C, Kappler M, Bifulco CB, Wickenhauser C, Seliger B, Fox BA, Bell RB. Head Neck. 2020 Oct 23. doi: 10.1002/hed.26520. Online ahead of print. PMID: 33094869

High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy. Riemann D, Schütte W, Turzer S, Seliger B, Möller M. Cancers (Basel). 2020 Oct 13;12(10):2966. doi: 10.3390/cancers12102966. PMID: 33066260

Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma. Friedrich M, Stoehr C, Jasinski-Bergner S, Hartmann A, Wach S, Wullich B, Steven A, Seliger B. J Transl Med. 2020 Sep 29;18(1):371. doi: 10.1186/s12967-020-02544-0. PMID: 32993793

Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins. Bauer M, Vaxevanis C, Heimer N, Al-Ali HK, Jaekel N, Bachmann M, Wickenhauser C, Seliger B. Int J Mol Sci. 2020 Sep 27;21(19):7140. doi: 10.3390/ijms21197140. PMID: 32992663

Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.Seliger B, Massa C, Yang B, Bethmann D, Kappler M, Eckert AW, Wickenhauser C. Int J Mol Sci. 2020 Sep 24;21(19):7032. doi: 10.3390/ijms21197032. PMID: 32987799 Review.

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A, Aranda F, Durand S, Boissonnas A, Fucikova J, Senovilla L, Enot D, Hensler M, Kremer M, Stoll G, Hu Y, Massa C, Formenti SC, Seliger B, Elemento O, Spisek R, André F, Zitvogel L, Delaloge S, Kroemer G, Galluzzi L. Nat Commun. 2020 Sep 17;11(1):4787. doi: 10.1038/s41467-020-18719-8. PMID: 32943636

Current Understanding of the HIF-1-Dependent Metabolism in Oral Squamous Cell Carcinoma. Eckert AW, Kappler M, Große I, Wickenhauser C, Seliger B. Int J Mol Sci. 2020 Aug 24;21(17):6083. doi: 10.3390/ijms21176083. PMID: 32846951 Review.

Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma. Lazaridou MF, Massa C, Handke D, Mueller A, Friedrich M, Subbarayan K, Tretbar S, Dummer R, Koelblinger P, Seliger B. J Clin Med. 2020 Aug 20;9(9):2690. doi: 10.3390/jcm9092690. PMID: 32825219

Comprehensive flow cytometric reference intervals of leukocyte subsets from six study centers across Europe. Oras A, Quirant-Sanchez B, Popadic D, Thunberg S, Winqvist O, Heck S, Cwikowski M, Riemann D, Seliger B, Martinez Caceres E, Uibo R, Giese T. Clin Exp Immunol. 2020 Dec;202(3):363-378. doi: 10.1111/cei.13491. Epub 2020 Aug 3. PMID: 32654132

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A, Aranda F, Durand S, Boissonnas A, Fucikova J, Senovilla L, Enot D, Hensler M, Kremer M, Stoll G, Hu Y, Massa C, Formenti SC, Seliger B, Elemento O, Spisek R, André F, Zitvogel L, Delaloge S, Kroemer G, Galluzzi L. Nat Commun. 2020 Jul 30;11(1):3819. doi: 10.1038/s41467-020-17644-0. PMID: 32732875

The Role of the RNA-Binding Protein Family MEX-3 in Tumorigenesis. Jasinski-Bergner S, Steven A, Seliger B. Int J Mol Sci. 2020 Jul 23;21(15):5209. doi: 10.3390/ijms21155209. PMID: 32717840 Review.

Molecular mechanisms of human herpes viruses inferring with host immune surveillance. Jasinski-Bergner S, Mandelboim O, Seliger B. J Immunother Cancer. 2020 Jul;8(2):e000841. doi: 10.1136/jitc-2020-000841. PMID: 32616556 Review.

Sialylation of Human Natural Killer (NK) Cells is Regulated by IL-2. Rosenstock P, Bork K, Massa C, Selke P, Seliger B, Horstkorte R. J Clin Med. 2020 Jun 11;9(6):1816. doi: 10.3390/jcm9061816. PMID: 32545211 

Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients. Lazaridou MF, Gonschorek E, Massa C, Friedrich M, Handke D, Mueller A, Jasinski-Bergner S, Dummer R, Koelblinger P, Seliger B. Oncoimmunology. 2020 Jun 3;9(1):1774323. doi: 10.1080/2162402X.2020.1774323. PMID: 32923135

Targeting the coding sequence: opposing roles in regulating classical and non-classical MHC class I molecules by miR-16 and miR-744. Friedrich M, Vaxevanis CK, Biehl K, Mueller A, Seliger B. J Immunother Cancer. 2020 Jun;8(1):e000396. doi: 10.1136/jitc-2019-000396. PMID: 32571994

DRH1 - a novel blood-based HPV tumour marker. Weiland T, Eckert A, Tomazic PV, Wolf A, Pondorfer P, Vasicek S, Graupp M, Holzmeister C, Moser U, Andrianakis A, Kangler G, Kiss P, Brcic L, Kappler M, Wickenhauser C, Haak A, Krüger M, Al-Nawas B, Blatt S, Brockmeyer N, Skaletz-Rorowski A, Potthoff A, French LE, Charnowski S, Reinholz M, Kaufmann AM, Thies S, Lambrecht HG, Seliger B, Wild DC, Thurnher D. EBioMedicine. 2020 Jun;56:102804. doi: 10.1016/j.ebiom.2020.102804. Epub 2020 Jun 11. PMID: 32535546

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. Reches A, Ophir Y, Stein N, Kol I, Isaacson B, Charpak Amikam Y, Elnekave A, Tsukerman P, Kucan Brlic P, Lenac T, Seliger B, Jonjic S, Mandelboim O. J Immunother Cancer. 2020 Jun;8(1):e000266. doi: 10.1136/jitc-2019-000266. PMID: 32503945

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated. Al Hashmi M, Sastry KS, Silcock L, Chouchane L, Mattei V, James N, Mathew R, Bedognetti D, De Giorgi V, Murtas D, Liu W, Chouchane A, Temanni R, Seliger B, Wang E, Marincola FM, Tomei S. J Transl Med. 2020 May 11;18(1):192. doi: 10.1186/s12967-020-02350-8. PMID: 32393282

What turns CREB on? And off? And why does it matter? Steven A, Friedrich M, Jank P, Heimer N, Budczies J, Denkert C, Seliger B. Cell Mol Life Sci. 2020 Oct;77(20):4049-4067. doi: 10.1007/s00018-020-03525-8. Epub 2020 Apr 28. PMID: 32347317 Review.

CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma. Friedrich M, Heimer N, Stoehr C, Steven A, Wach S, Taubert H, Hartmann A, Seliger B. Sci Rep. 2020 Apr 16;10(1):6499. doi: 10.1038/s41598-020-63403-y. PMID: 32300145

"UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, Loureiro LR, Bergmann R, Máthé D, Hegedüs N, Kovács T, Zhang C, Oberoi P, Jäger E, Seliger B, Rössig C, Temme A, Eitler J, Tonn T, Schmitz M, Hassel JC, Jäger D, Wels WS, Bachmann M. Sci Rep. 2020 Feb 7;10(1):2141. doi: 10.1038/s41598-020-59082-4. PMID: 32034289 

"Tumor immunology meets oncology (TIMO) XV", April 25th-27th 2019, Halle/Saale, Germany. Steven A, Massa C, Seliger B. Cancer Immunol Immunother. 2020 May;69(5):901-909. doi: 10.1007/s00262-020-02491-1. Epub 2020 Feb 5. PMID: 32025850

Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade. Möller M, Turzer S, Schütte W, Seliger B, Riemann D. J Immunother. 2020 Feb/Mar;43(2):57-66. doi: 10.1097/CJI.0000000000000297. PMID: 31592989

HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.Seliger B, Ferrone S. Methods Mol Biol. 2020;2055:325-350. doi: 10.1007/978-1-4939-9773-2_15. PMID: 31502159 Review.

Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display. Wickström SL, Lövgren T, Volkmar M, Reinhold B, Duke-Cohan JS, Hartmann L, Rebmann J, Mueller A, Melief J, Maas R, Ligtenberg M, Hansson J, Offringa R, Seliger B, Poschke I, Reinherz EL, Kiessling R. Front Immunol. 2019 Dec 11;10:2766. doi: 10.3389/fimmu.2019.02766. eCollection 2019. PMID: 31921104 Free PMC article.

NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells. Bosch NC, Voll RE, Voskens CJ, Gross S, Seliger B, Schuler G, Schaft N, Dörrie J. Ther Adv Med Oncol. 2019 Dec 11;11:1758835919891622. doi: 10.1177/1758835919891622. eCollection 2019. PMID: 31853267 Free PMC article.

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Sinn BV, Weber KE, Schmitt WD, Fasching PA, Symmans WF, Blohmer JU, Karn T, Taube ET, Klauschen F, Marmé F, Schem C, Stickeler E, Ataseven B, Huober J, von Minckwitz G, Seliger B, Denkert C, Loibl S. Breast Cancer Res. 2019 Dec 11;21(1):142. doi: 10.1186/s13058-019-1231-z. PMID: 31829264 Free PMC article.

Basis of PD1/PD-L1 Therapies.Seliger B. J Clin Med. 2019 Dec 8;8(12):2168. doi: 10.3390/jcm8122168. PMID: 31817953 Free PMC article. Review.

PIR-B expressing CD8+ T cells exhibit features of Tc1 and Tc17 in SKG mice. Rothe K, Quandt D, Köhler G, Jasinski-Bergner S, Seliger B, Pierer M, Wagner U. Rheumatology (Oxford). 2019 Dec 1;58(12):2325-2329. doi: 10.1093/rheumatology/kez256. PMID: 31257448

Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma. Fänder J, Kielstein H, Büttner M, Koelblinger P, Dummer R, Bauer M, Handke D, Wickenhauser C, Seliger B, Jasinski-Bergner S. Oncotarget. 2019 Nov 5;10(60):6509-6525. doi: 10.18632/oncotarget.27305. eCollection 2019 Nov 5. PMID: 31741714 Free PMC article.

Causes and Consequences of A Glutamine Induced Normoxic HIF1 Activity for the Tumor Metabolism. Kappler M, Pabst U, Weinholdt C, Taubert H, Rot S, Kaune T, Kotrba J, Porsch M, Güttler A, Bache M, Krohn K, Bull F, Riemann A, Wickenhauser C, Seliger B, Schubert J, Al-Nawas B, Thews O, Grosse I, Vordermark D, Eckert AW. Int J Mol Sci. 2019 Sep 24;20(19):4742. doi: 10.3390/ijms20194742. PMID: 31554283 Free PMC article.

The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review. Seliger B. Front Immunol. 2019 Sep 6;10:2043. doi: 10.3389/fimmu.2019.02043. eCollection 2019. PMID: 31555274 Free PMC article. Review.

Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy. Friedrich M, Jasinski-Bergner S, Lazaridou MF, Subbarayan K, Massa C, Tretbar S, Mueller A, Handke D, Biehl K, Bukur J, Donia M, Mandelboim O, Seliger B. Cancer Immunol Immunother. 2019 Oct;68(10):1689-1700. doi: 10.1007/s00262-019-02373-1. Epub 2019 Aug 3. PMID: 31375885 Review.

Multiplex immunohistochemistry as a novel tool for the topographic assessment of the bone marrow stem cell niche. Bauer M, Vaxevanis C, Bethmann D, Massa C, Pazaitis N, Wickenhauser C, Seliger B. Methods Enzymol. 2020;635:67-79. doi: 10.1016/bs.mie.2019.05.055. Epub 2019 Jun 18. PMID: 32122554

Identification of immunomodulatory RNA-binding proteins in tumors. Friedrich M, Lazaridou MF, Rahn J, Vaxevanis C, Heimer N, Jasinski-Bergner S, Seliger B. Methods Enzymol. 2020;636:339-350. doi: 10.1016/bs.mie.2019.05.042. Epub 2019 Jun 17. PMID: 32178825

An altered miTRAP method for miRNA affinity purification with its pros and cons. Jasinski-Bergner S, Vaxevanis C, Heimer N, Lazaridou MF, Friedrich M, Seliger B. Methods Enzymol. 2020;636:323-337. doi: 10.1016/bs.mie.2019.05.016. Epub 2019 Jun 8. PMID: 32178824

Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity.Seliger B. Front Immunol. 2019 May 22;10:999. doi: 10.3389/fimmu.2019.00999. eCollection 2019. PMID: 31178856 Free PMC article. Review.

Monoallelic expression in melanoma.

Silcock L, Almabrazi H, Mokrab Y, Jithesh P, Al-Hashmi M, James N, Mathew R, Mattei V, Bedognetti D, Lessi F, Temanni R, Seliger B, Al-Ali R, Marincola FM, Wang E, Tomei S. J Transl Med. 2019 Apr 5;17(1):112. doi: 10.1186/s12967-019-1863-x. PMID: 30953523 Free PMC article.

"Tumor Immunology Meets Oncology (TIMO) XIV", May 24-26th 2018, Halle/Saale, Germany. Steven A, Seliger B. Cancer Immunol Immunother. 2019 Oct;68(10):1725-1732. doi: 10.1007/s00262-019-02329-5. Epub 2019 Apr 4. PMID: 30949754

TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma. Tretbar S, Krausbeck P, Müller A, Friedrich M, Vaxevanis C, Bukur J, Jasinski-Bergner S, Seliger B. Oncotarget. 2019 Feb 19;10(15):1507-1524. doi: 10.18632/oncotarget.26682. eCollection 2019 Feb 19. PMID: 30863498 Free PMC article.

Identification of Immune Modulatory miRNAs by miRNA Enrichment via RNA Affinity Purification. Tretbar US, Friedrich M, Lazaridou MF, Seliger B. Methods Mol Biol. 2019;1913:81-101. doi: 10.1007/978-1-4939-8979-9_6. PMID: 30666600

Multispectral Fluorescence Imaging Allows for Distinctive Topographic Assessment and Subclassification of Tumor-Infiltrating and Surrounding Immune Cells. Wickenhauser C, Bethmann D, Feng Z, Jensen SM, Ballesteros-Merino C, Massa C, Steven A, Bauer M, Kaatzsch P, Pazaitis N, Toma G, Bifulco CB, Fox BA, Seliger B. Methods Mol Biol. 2019;1913:13-31. doi: 10.1007/978-1-4939-8979-9_2. PMID: 30666596

Tumor-dependent Effects of Proteoglycans and Various Glycosaminoglycan Synthesizing Enzymes and Sulfotransferases on Patients' Outcome. Subbarayan K, Seliger B. Curr Cancer Drug Targets. 2019;19(3):210-221. doi: 10.2174/1568009618666180706165845. PMID: 29984655

The tumor microenvironment: Thousand obstacles for effector T cells. Massa C, Seliger B. Cell Immunol. 2019 Sep;343:103730. doi: 10.1016/j.cellimm.2017.12.004. Epub 2017 Dec 8. PMID: 29249298

Identification of a novel lncRNA induced by the nephrotoxin ochratoxin A and expressed in human renal tumor tissue. Polovic M, Dittmar S, Hennemeier I, Humpf HU, Seliger B, Fornara P, Theil G, Azinovic P, Nolze A, Köhn M, Schwerdt G, Gekle M. Cell Mol Life Sci. 2018 Jun;75(12):2241-2256. doi: 10.1007/s00018-017-2731-6. Epub 2017 Dec 27. PMID: 29282485

The tumor microenvironment: Thousand obstacles for effector T cells. Massa C, Seliger B. Cell Immunol. 2019 Sep;343:103730. doi: 10.1016/j.cellimm.2017.12.004. Epub 2017 Dec 8. PMID: 29249298

Loss of epithelium-specific GPx2 results in aberrant cell fate decisions during intestinal differentiation. Lennicke C, Rahn J, Wickenhauser C, Lichtenfels R, Müller AS, Wessjohann LA, Kipp AP, Seliger B. Oncotarget. 2017 Nov 23;9(1):539-552. doi: 10.18632/oncotarget.22640. eCollection 2018 Jan 2. PMID: 29416634 Free PMC article.

Linking CREB function with altered metabolism in murine fibroblast-based model cell lines. Steven A, Leisz S, Wickenhauser C, Schulz K, Mougiakakos D, Kiessling R, Denkert C, Seliger B. Oncotarget. 2017 Oct 27;8(57):97439-97463. doi: 10.18632/oncotarget.22135. eCollection 2017 Nov 14. PMID: 29228623 Free PMC article.

Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape. Eichmüller SB, Osen W, Mandelboim O, Seliger B. J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx034. PMID: 28383653 Review.

The role of the miR-148/-152 family in physiology and disease. Friedrich M, Pracht K, Mashreghi MF, Jäck HM, Radbruch A, Seliger B. Eur J Immunol. 2017 Dec;47(12):2026-2038. doi: 10.1002/eji.201747132. Epub 2017 Sep 29. PMID: 28880997 Review.

Multiparametric immune profiling in HPV- oral squamous cell cancer. Feng Z, Bethmann D, Kappler M, Ballesteros-Merino C, Eckert A, Bell RB, Cheng A, Bui T, Leidner R, Urba WJ, Johnson K, Hoyt C, Bifulco CB, Bukur J, Wickenhauser C, Seliger B, Fox BA. JCI Insight. 2017 Jul 20;2(14):e93652. doi: 10.1172/jci.insight.93652. eCollection 2017 Jul 20. PMID: 28724788 Free PMC article.

Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B. Oncotarget. 2017 Jul 18;8(29):48507-48520. doi: 10.18632/oncotarget.17397. PMID: 28501851 Free PMC article. Review.

Immune modulatory microRNAs as a novel mechanism to revert immune escape of tumors.Seliger B. Cytokine Growth Factor Rev. 2017 Aug;36:49-56. doi: 10.1016/j.cytogfr.2017.07.001. Epub 2017 Jul 13.

PMID: 28739030 Review.

"Tumor immunology meets oncology (TIMO) XII", April 28th-30th 2016, Halle/Saale, Germany.Seliger B. Cancer Immunol Immunother. 2017 Nov;66(11):1497-1503. doi: 10.1007/s00262-017-2037-4. Epub 2017 Jul 10. PMID: 28695228

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling. Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM. Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27. PMID: 28655789

AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Hüttelmaier S, Müller-Tidow C. Nat Cell Biol. 2017 Jul;19(7):844-855. doi: 10.1038/ncb3563. Epub 2017 Jun 26. PMID: 28650479

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM. Eur J Cancer. 2017 Aug;81:116-129. doi: 10.1016/j.ejca.2017.01.035. Epub 2017 Jun 15. PMID: 28623775 Review.

Altered protein expression pattern in colon tissue of mice upon supplementation with distinct selenium compounds. Rahn J, Lennicke C, Kipp AP, Müller AS, Wessjohann LA, Lichtenfels R, Seliger B. Proteomics. 2017 Jun;17(11). doi: 10.1002/pmic.201600486. PMID: 28409884

Immunotherapy for metastatic renal cell carcinoma. Unverzagt S, Moldenhauer I, Nothacker M, Roßmeißl D, Hadjinicolaou AV, Peinemann F, Greco F, Seliger B. Cochrane Database Syst Rev. 2017 May 15;5(5):CD011673. doi: 10.1002/14651858.CD011673.pub2. PMID: 28504837 Free PMC article. Review.

High constitutive B7-H3 expression on human keratinocytes supports T cell immunity. Quandt D, Fiedler E, Müller A, Marsch WC, Seliger B. J Dermatol Sci. 2017 Jul;87(1):82-85. doi: 10.1016/j.jdermsci.2017.02.287. Epub 2017 Apr 11. PMID: 28465042

Methionine and seleno-methionine type peptide and peptoid building blocks synthesized by five-component five-center reactions. Kaluđerović GN, Abbas M, Kautz HC, Wadaan MA, Lennicke C, Seliger B, Wessjohann LA. Chem Commun (Camb). 2017 Mar 28;53(26):3777-3780. doi: 10.1039/c7cc00399d. PMID: 28304024

Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients. Massa C, Robins H, Desmarais C, Riemann D, Fahldieck C, Fornara P, Seliger B. Oncotarget. 2017 Mar 28;8(13):21212-21228. doi: 10.18632/oncotarget.15064. PMID: 28177902 Free PMC article.

Immunotherapy biomarkers 2016: overcoming the barriers. Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH. J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6. PMID: 28653584 Free PMC article.

Systematic evaluation of immune regulation and modulation. Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B.J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. PMID: 28331613 Free PMC article. Review.

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, Curigliano G, Seliger B, Cerulo L, Tomei S, Delogu LG, Maccalli C, Wang E, Miller LD, Marincola FM, Ceccarelli M, Bedognetti D. Oncoimmunology. 2017 Feb 6;6(2):e1253654. doi: 10.1080/2162402X.2016.1253654. eCollection 2017.

PMID: 28344865 Free PMC article.

HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.Seliger B, Kloor M, Ferrone S. Oncoimmunology. 2017 Feb 6;6(2):e1171447. doi: 10.1080/2162402X.2016.1171447. eCollection 2017. PMID: 28344859 Free PMC article. Review.

Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion. Juengel E, Krueger G, Rutz J, Nelson K, Werner I, Relja B, Seliger B, Fisslthaler B, Fleming I, Tsaur I, Haferkamp A, Blaheta RA. Oncotarget. 2017 Jan 3;8(1):1953-1954. doi: 10.18632/oncotarget.14438.

PMID: 28131102 Free PMC article.

Adiponectin and Its Receptors Are Differentially Expressed in Human Tissues and Cell Lines of Distinct Origin. Jasinski-Bergner S, Büttner M, Quandt D, Seliger B, Kielstein H. Obes Facts. 2017;10(6):569-583. doi: 10.1159/000481732. Epub 2017 Dec 6. PMID: 29207395 Free PMC article.

Individual effects of different selenocompounds on the hepatic proteome and energy metabolism of mice. Lennicke C, Rahn J, Kipp AP, Dojčinović BP, Müller AS, Wessjohann LA, Lichtenfels R, Seliger B. Biochim Biophys Acta Gen Subj. 2017 Jan;1861(1 Pt A):3323-3334. doi: 10.1016/j.bbagen.2016.08.015. Epub 2016 Aug 24. PMID: 27565357

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. Budczies J, Seidel A, Christopoulos P, Endris V, Kloor M, Győrffy B, Seliger B, Schirmacher P, Stenzinger A, Denkert C. Oncoimmunology. 2018 Oct 19;7(12):e1526613. doi: 10.1080/2162402X.2018.1526613. eCollection 2018. PMID: 30524909 Free PMC article.

Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma. Steven A, Leisz S, Fussek S, Nowroozizadeh B, Huang J, Branstetter D, Dougall WC, Burchardt M, Belldegrun AS, Seliger B, Pantuck A, Kroeger N. Urol Oncol. 2018 Nov;36(11):502.e15-502.e24. doi: 10.1016/j.urolonc.2018.07.013. Epub 2018 Aug 28. PMID: 30170981

Kallikrein-related peptidases are activators of the CC chemokine CCL14. Grünberg M, Quandt D, Cynis H, Demuth HU, Kindermann A, Magdolen V, Forssmann WG, Seliger B, Mägert HJ. Eur J Immunol. 2018 Sep;48(9):1592-1594. doi: 10.1002/eji.201747452. Epub 2018 Aug 22. PMID: 30028015

Correction to: Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma. Eckert AW, Wickenhauser C, Salins PC, Kappler M, Bukur J, Seliger B. J Transl Med. 2018 Feb 28;16(1):40. doi: 10.1186/s12967-018-1407-9. PMID: 29486780 Free PMC article.

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O. Immunity. 2018 Feb 20;48(2):396-398. doi: 10.1016/j.immuni.2018.01.010. PMID: 29466761 Free PMC article.

Immunotherapy of Breast Cancer.Seliger B. Breast Care (Basel). 2018 Mar;13(1):5-6. doi: 10.1159/000486927. Epub 2018 Feb 13. PMID: 29950960 Free PMC article.

The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. Steven A, Seliger B. Breast Care (Basel). 2018 Mar;13(1):16-21. doi: 10.1159/000486585. Epub 2018 Feb 2. PMID: 29950962 Free PMC article. Review.

Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells. Subbarayan K, Leisz S, Wickenhauser C, Bethmann D, Massa C, Steven A, Seliger B. Oncoimmunology. 2018 Jan 16;7(4):e1373233. doi: 10.1080/2162402X.2017.1373233. eCollection 2018. PMID: 29632715 Free PMC article.

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O. Immunity. 2018 Jan 16;48(1):107-119.e4. doi: 10.1016/j.immuni.2017.12.007. Epub 2018 Jan 9. PMID: 29329948

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy. Andersen R, Westergaard MCW, Kjeldsen JW, Müller A, Pedersen NW, Hadrup SR, Met Ö, Seliger B, Kromann-Andersen B, Hasselager T, Donia M, Svane IM. Cancer Immunol Res. 2018 Feb;6(2):222-235. doi: 10.1158/2326-6066.CIR-17-0467. Epub 2018 Jan 4. PMID: 29301752

Identification of a novel lncRNA induced by the nephrotoxin ochratoxin A and expressed in human renal tumor tissue. Polovic M, Dittmar S, Hennemeier I, Humpf HU, Seliger B, Fornara P, Theil G, Azinovic P, Nolze A, Köhn M, Schwerdt G, Gekle M. Cell Mol Life Sci. 2018 Jun;75(12):2241-2256. doi: 10.1007/s00018-017-2731-6. Epub 2017 Dec 27. PMID: 29282485

VHL-dependent alterations in the secretome of renal cell carcinoma: Association with immune cell response? Stehle F, Leisz S, Schulz K, Schwurack N, Weber N, Massa C, Kalich J, Fahldieck C, Seliger B. Oncotarget. 2015 Dec 22;6(41):43420-37. doi: 10.18632/oncotarget.5560. PMID: 26486078 Free PMC article.

Redox proteomics: Methods for the identification and enrichment of redox-modified proteins and their applications. Lennicke C, Rahn J, Heimer N, Lichtenfels R, Wessjohann LA, Seliger B. Proteomics. 2016 Jan;16(2):197-213. doi: 10.1002/pmic.201500268. Epub 2015 Dec 17. PMID: 26508685 Review.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1. PMID: 26619946 Free PMC article.

Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells. Okita R, Wolf D, Yasuda K, Maeda A, Yukawa T, Saisho S, Shimizu K, Yamaguchi Y, Oka M, Nakayama E, Lundqvist A, Kiessling R, Seliger B, Nakata M. PLoS One. 2015 Oct 6;10(10):e0139809. doi: 10.1371/journal.pone.0139809. eCollection 2015. PMID: 26439264 Free PMC article.

Hydrogen peroxide - production, fate and role in redox signaling of tumor cells.

Lennicke C, Rahn J, Lichtenfels R, Wessjohann LA, Seliger B.

Cell Commun Signal. 2015 Sep 14;13:39. doi: 10.1186/s12964-015-0118-6.

PMID: 26369938 Free PMC article. Review.

Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. Andersson E, Poschke I, Villabona L, Carlson JW, Lundqvist A, Kiessling R, Seliger B, Masucci GV. Oncoimmunology. 2015 Jul 25;5(1):e1052213. doi: 10.1080/2162402X.2015.1052213. eCollection 2016. PMID: 26942060 Free PMC article.

Different maturation cocktails provide dendritic cells with different chemoattractive properties. Massa C, Thomas C, Wang E, Marincola F, Seliger B.

J Transl Med. 2015 Jun 3;13:175. doi: 10.1186/s12967-015-0528-7. PMID: 26695182 Free PMC article.

Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism. Leisz S, Schulz K, Erb S, Oefner P, Dettmer K, Mougiakakos D, Wang E, Marincola FM, Stehle F, Seliger B. Oncotarget. 2015 May 10;6(13):11395-406. doi: 10.18632/oncotarget.3456. PMID: 25890500 Free PMC article.

"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014. Maio M, Bertocci E, Pilla L, Fazio C, Chiarucci C, Cutaia O, Fonsatti E, Maccalli C, Parmiani G; NIBIT. Cancer Immunol Immunother. 2016 Jan;65(1):119-26. doi: 10.1007/s00262-015-1699-z. Epub 2015 May 6. PMID: 25944004

Colorectal Carcinogenesis: Connecting K-RAS-Induced Transformation and CREB Activity In Vitro and In Vivo. Steven A, Heiduk M, Recktenwald CV, Hiebl B, Wickenhauser C, Massa C, Seliger B. Mol Cancer Res. 2015 Aug;13(8):1248-62. doi: 10.1158/1541-7786.MCR-14-0590. Epub 2015 May 1.

PMID: 25934695

Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. Jasinski-Bergner S, Stoehr C, Bukur J, Massa C, Braun J, Hüttelmaier S, Spath V, Wartenberg R, Legal W, Taubert H, Wach S, Wullich B, Hartmann A, Seliger B. Oncoimmunology. 2015 Mar 2;4(6):e1008805. doi: 10.1080/2162402X.2015.1008805. eCollection 2015 Jun.

PMID: 26155421 Free PMC article.

Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis. Toma M, Wehner R, Kloß A, Hübner L, Fodelianaki G, Erdmann K, Füssel S, Zastrow S, Meinhardt M, Seliger B, Brech D, Noessner E, Tonn T, Schäkel K, Bornhäuser M, Bachmann MP, Wirth MP, Baretton G, Schmitz M. Oncoimmunology. 2015 Mar 2;4(6):e1008342. doi: 10.1080/2162402X.2015.1008342. eCollection 2015 Jun.

PMID: 26155414 Free PMC article.

Molecular mechanism of CHRDL1-mediated X-linked megalocornea in humans and in Xenopus model. Pfirrmann T, Emmerich D, Ruokonen P, Quandt D, Buchen R, Fischer-Zirnsak B, Hecht J, Krawitz P, Meyer P, Klopocki E, Stricker S, Lausch E, Seliger B, Hollemann T, Reinhard T, Auw-Haedrich C, Zabel B, Hoffmann K, Villavicencio-Lorini P. Hum Mol Genet. 2015 Jun 1;24(11):3119-32. doi: 10.1093/hmg/ddv063. Epub 2015 Feb 23. PMID: 25712132

"Tumor immunology meets oncology" (TIMO) X, May 23-24, 2014, Halle/Saale, Germany. Quandt D, Seliger B. Cancer Immunol Immunother. 2015 Apr;64(4):519-26. doi: 10.1007/s00262-015-1661-0. Epub 2015 Feb 14. PMID: 25680628

Immune signature of tumor infiltrating immune cells in renal cancer. Geissler K, Fornara P, Lautenschläger C, Holzhausen HJ, Seliger B, Riemann D. Oncoimmunology. 2015 Feb 3;4(1):e985082. doi: 10.4161/2162402X.2014.985082. eCollection 2015 Jan. PMID: 25949868 Free PMC article.

Tregs activated by bispecific antibodies: Killers or suppressors? Koristka S, Cartellieri M, Arndt C, Feldmann A, Seliger B, Ehninger G, Bachmann MP. Oncoimmunology. 2015 Jan 23;4(3):e994441. doi: 10.4161/2162402X.2014.994441. eCollection 2015 Mar. PMID: 25949920 Free PMC article.

Impact of the mitogen-activated protein kinase pathway on the subproteome of detergent-resistant microdomains of colon carcinoma cells. Recktenwald CV, Lichtenfels R, Wulfaenger J, Müller A, Dressler SP, Seliger B. Proteomics. 2015 Jan;15(1):77-88. doi: 10.1002/pmic.201300321. PMID: 25359454

Screening of synthetic and natural product databases: Identification of novel androgens and antiandrogens. Bobach C, Tennstedt S, Palberg K, Denkert A, Brandt W, de Meijere A, Seliger B, Wessjohann LA. Eur J Med Chem. 2015 Jan 27;90:267-79. doi:  10.1016/j.ejmech.2014.11.026. Epub 2014 Nov 13. PMID: 25461327

Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid. Lennicke C, Rahn J, Bukur J, Hochgräfe F, Wessjohann LA, Lichtenfels R, Seliger B. Oncoimmunology. 2016 Dec 21;6(6):e1259049. doi: 10.1080/2162402X.2016.1259049. eCollection 2017. PMID: 28680742 Free PMC article.

HLA-E expression and its clinical relevance in human renal cell carcinoma.Seliger B, Jasinski-Bergner S, Quandt D, Stoehr C, Bukur J, Wach S, Legal W, Taubert H, Wullich B, Hartmann A. Oncotarget. 2016 Oct 11;7(41):67360-67372. doi: 10.18632/oncotarget.11744. PMID: 27589686 Free PMC article.

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, Blank C, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M. Cell Metab. 2016 Nov 8;24(5):657-671. doi: 10.1016/j.cmet.2016.08.011. Epub 2016 Sep 15. PMID: 27641098

"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015.

Maio M, Bertocci E, Fazio C, Chiarucci C, Cutaia O, Scala E, Giacobini G, Lofiego MF, Fonsatti E, Maccalli C, Nicolay HJ, Parmiani G; NIBIT. Cancer Immunol Immunother. 2016 Nov;65(11):1423-1431. doi: 10.1007/s00262-016-1899-1. Epub 2016 Sep 12. PMID: 27619513

Individual effects of different selenocompounds on the hepatic proteome and energy metabolism of mice. Lennicke C, Rahn J, Kipp AP, Dojčinović BP, Müller AS, Wessjohann LA, Lichtenfels R, Seliger B. Biochim Biophys Acta Gen Subj. 2017 Jan;1861(1 Pt A):3323-3334. doi: 10.1016/j.bbagen.2016.08.015. Epub 2016 Aug 24. PMID: 27565357

Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization. Steven A, Leisz S, Sychra K, Hiebl B, Wickenhauser C, Mougiakakos D, Kiessling R, Denkert C, Seliger B. Oncotarget. 2016 Aug 9;7(32):52061-52084. doi: 10.18632/oncotarget.10474. PMID: 27409833 Free PMC article.

Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target. Steven A, Seliger B. Oncotarget. 2016 Jun 7;7(23):35454-65. doi: 10.18632/oncotarget.7721. PMID: 26934558 Free PMC article. Review.

HNRNPR Regulates the Expression of Classical and Nonclassical MHC Class I Proteins. Reches A, Nachmani D, Berhani O, Duev-Cohen A, Shreibman D, Ophir Y, Seliger B, Mandelboim O. J Immunol. 2016 Jun 15;196(12):4967-76. doi: 10.4049/jimmunol.1501550. Epub 2016 May 18. PMID: 27194785

Harnessing the immune system for the treatment of melanoma: current status and future prospects. Guennoun A, Sidahmed H, Maccalli C, Seliger B, Marincola FM, Bedognetti D. Expert Rev Clin Immunol. 2016 Aug;12(8):879-93. doi: 10.1080/1744666X.2016.1176529. Epub 2016 May 3. PMID: 27070898 Review.

Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma. Jasinski-Bergner S, Reches A, Stoehr C, Massa C, Gonschorek E, Huettelmaier S, Braun J, Wach S, Wullich B, Spath V, Wang E, Marincola FM, Mandelboim O, Hartmann A, Seliger B. Oncotarget. 2016 May 3;7(18):26866-78. doi: 10.18632/oncotarget.8567. PMID: 27057628 Free PMC article.

Role of microRNAs on HLA-G expression in human tumors.Seliger B. Hum Immunol. 2016 Sep;77(9):760-3. doi: 10.1016/j.humimm.2016.04.006. Epub 2016 Apr 30. PMID: 27142884 Review.

Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion. Juengel E, Krueger G, Rutz J, Nelson K, Werner I, Relja B, Seliger B, Fisslthaler B, Fleming I, Tsaur I, Haferkamp A, Blaheta RA. Oncotarget. 2016 Apr 12;7(15):20410-24. doi: 10.18632/oncotarget.7804. PMID: 26943029 Free PMC article.

"Tumor immunology meets oncology" (TIMO) XI, May 22-23, 2015, Halle/Saale, Germany. Quandt D, Seliger B. Cancer Immunol Immunother. 2016 May;65(5):625-30. doi: 10.1007/s00262-016-1833-6. Epub 2016 Apr 8. PMID: 27060001

Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma. Eckert AW, Wickenhauser C, Salins PC, Kappler M, Bukur J, Seliger B. J Transl Med. 2016 Apr 5;14:85. doi: 10.1186/s12967-016-0828-6. PMID: 27044404 Free PMC article. Review.

Checkpoint Inhibitors and Their Application in Breast Cancer. Bedognetti D, Maccalli C, Bader SB, Marincola FM, Seliger B. Breast Care (Basel). 2016 Apr;11(2):108-15. doi: 10.1159/000445335. Epub 2016 Apr 26. PMID: 27239172 Free PMC article. Review.

Disentangling the relationship between tumor genetic programs and immune responsiveness. Bedognetti D, Hendrickx W, Ceccarelli M, Miller LD, Seliger B.

Curr Opin Immunol. 2016 Apr;39:150-8. doi: 10.1016/j.coi.2016.02.001. Epub 2016 Mar 9. PMID: 26967649 Review.

Latent Cytomegalovirus Infection in Rheumatoid Arthritis and Increased Frequencies of Cytolytic LIR-1+CD8+ T Cells. Rothe K, Quandt D, Schubert K, Rossol M, Klingner M, Jasinski-Bergner S, Scholz R, Seliger B, Pierer M, Baerwald C, Wagner U. Arthritis Rheumatol. 2016 Feb;68(2):337-46. doi: 10.1002/art.39331. PMID: 26314621 Free PMC article.

Redox proteomics: Methods for the identification and enrichment of redox-modified proteins and their applications. Lennicke C, Rahn J, Heimer N, Lichtenfels R, Wessjohann LA, Seliger B. Proteomics. 2016 Jan;16(2):197-213. doi: 10.1002/pmic.201500268. Epub 2015 Dec 17. PMID: 26508685 Review.

"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014. Maio M, Bertocci E, Pilla L, Fazio C, Chiarucci C, Cutaia O, Fonsatti E, Maccalli C, Parmiani G; NIBIT. Cancer Immunol Immunother. 2016 Jan;65(1):119-26. doi: 10.1007/s00262-015-1699-z. Epub 2015 May 6. PMID: 25944004

Classification of current anticancer immunotherapies. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998. PMID: 25537519 Free PMC article. Review.

Screening of synthetic and natural product databases: Identification of novel androgens and antiandrogens. Bobach C, Tennstedt S, Palberg K, Denkert A, Brandt W, de Meijere A, Seliger B, Wessjohann LA. Eur J Med Chem. 2015 Jan 27;90:267-79. doi: 10.1016/j.ejmech.2014.11.026. Epub 2014 Nov 13. PMID: 25461327

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. J Transl Med. 2014 Oct 28;12:277. doi: 10.1186/s12967-014-0277-z. PMID: 25348889 Free PMC article.

Interleukin-1 potently contributes to 25-hydroxycholesterol-induced synergistic cytokine production in smooth muscle cell-monocyte interactions. Fu H, Spieler F, Großmann J, Riemann D, Larisch M, Hiebl B, Schlecht K, Jaschke C, Bartling B, Hofmann B, Unverzagt S, Koch S, Pilowski C, Simm A, Silber RE, Gielen S, Seliger B, Schlitt A, Ebelt H, Müller-Werdan U, Buerke M, Werdan K, Loppnow H. Atherosclerosis. 2014 Dec;237(2):443-52. doi: 10.1016/j.atherosclerosis.2014.10.002. Epub 2014 Oct 5. PMID: 25463072

Identification of 14-3-3β gene as a novel miR-152 target using a proteome-based approach. Jasinski-Bergner S, Stehle F, Gonschorek E, Kalich J, Schulz K, Huettelmaier S, Braun J, Seliger B. J Biol Chem. 2014 Nov 7;289(45):31121-35. doi: 10.1074/jbc.M114.556290. Epub 2014 Sep 16. PMID: 25228695 Free PMC article.

The role of microRNAs in the control of innate immune response in cancer. Jasinski-Bergner S, Mandelboim O, Seliger B. J Natl Cancer Inst. 2014 Sep 12;106(10):dju257. doi: 10.1093/jnci/dju257. Print 2014 Oct. PMID: 25217579 Review.

Multiple readout assay for hormonal (androgenic and antiandrogenic) and cytotoxic activity of plant and fungal extracts based on differential prostate cancer cell line behavior. Bobach C, Schurwanz J, Franke K, Denkert A, Van Sung T, Kuster R, Mutiso PC, Seliger B, Wessjohann LA. J Ethnopharmacol. 2014 Aug 8;155(1):721-30. doi: 10.1016/j.jep.2014.06.008. Epub 2014 Jun 16. PMID: 24945396

Granulocyte-to-dendritic cell-ratio as marker for the immune monitoring in patients with renal cell carcinoma. Riemann D, Hase S, Fischer K, Seliger B. Clin Transl Med. 2014 Jun 6;3:13. doi: 10.1186/2001-1326-3-13. eCollection 2014. PMID: 24995120 Free PMC article.

Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A. Clin Cancer Res. 2014 Aug 1;20(15):4096-106. doi: 10.1158/1078-0432.CCR-14-0635. Epub 2014 Jun 6. PMID: 24907113

Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. Quandt D, Jasinski-Bergner S, Müller U, Schulze B, Seliger B. J Transl Med. 2014 May 30;12:151. doi: 10.1186/1479-5876-12-151. PMID: 24885059 Free PMC article.

"Tumor Immunology Meets Oncology (TIMO) IX", May 2-4, 2013, Halle/Saale, Germany.Seliger B. Cancer Immunol Immunother. 2014 Mar;63(3):305-11. doi: 10.1007/s00262-014-1522-2. Epub 2014 Feb 8. PMID: 24509955

A novel approach for HLA-A typing in formalin-fixed paraffin-embedded-derived DNA. Villabona L, Leon Rodriguez DA, Andersson EK, Seliger B, Dalianis T, Masucci GV. Mod Pathol. 2014 Sep;27(9):1296-305. doi: 10.1038/modpathol.2013.210. Epub 2014 Feb 7. PMID: 24504073

The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors.Seliger B. J Immunotoxicol. 2014 Oct;11(4):308-10. doi: 10.3109/1547691X.2013.875084. Epub 2014 Jan 30. PMID: 24479372 Review.

B7-H abnormalities in melanoma and clinical relevance.Seliger B. Methods Mol Biol. 2014;1102:367-80. doi: 10.1007/978-1-62703-727-3_19. PMID: 24258988

The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Seliger B, Massa C.

Front Immunol. 2013 Dec 2;4:419. doi: 10.3389/fimmu.2013.00419. PMID: 24348482 Free PMC article. Review.

Towards defining biomarkers indicating resistances to targeted therapies.

Stehle F, Schulz K, Seliger B. Biochim Biophys Acta. 2014 May;1844(5):909-16. doi: 10.1016/j.bbapap.2013.11.006. Epub 2013 Nov 20. PMID: 24269379 Review.

The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. Mimura K, Shiraishi K, Mueller A, Izawa S, Kua LF, So J, Yong WP, Fujii H, Seliger B, Kiessling R, Kono K. J Immunol. 2013 Dec 15;191(12):6261-72. doi: 10.4049/jimmunol.1301597. Epub 2013 Nov 15. PMID: 24244023 Free PMC article.

HLA-dependent tumour development: a role for tumour associate macrophages? Marchesi M, Andersson E, Villabona L, Seliger B, Lundqvist A, Kiessling R, Masucci GV. J Transl Med. 2013 Oct 6;11:247. doi: 10.1186/1479-5876-11-247.

PMID: 24093459 Free PMC article. Review.

The two sides of HER2/neu: immune escape versus surveillance.Seliger B, Kiessling R. Trends Mol Med. 2013 Nov;19(11):677-84. doi: 10.1016/j.molmed.2013.08.003. Epub 2013 Sep 12. PMID: 24035606 Review.

HER-2/neu mediates oncogenic transformation via altered CREB expression and function. Steven A, Leisz S, Massa C, Iezzi M, Lattanzio R, Lamolinara A, Bukur J, Müller A, Hiebl B, Holzhausen HJ, Seliger B. Mol Cancer Res. 2013 Nov;11(11):1462-77. doi: 10.1158/1541-7786.MCR-13-0125. Epub 2013 Sep 11. PMID: 24025972

Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma. Wulfänger J, Biehl K, Tetzner A, Wild P, Ikenberg K, Meyer S, Seliger B. Int J Cancer. 2013 Dec 1;133(11):2522-32. doi: 10.1002/ijc.28278. Epub 2013 Jun 14. PMID: 23686552

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. J Transl Med. 2013 Jun 3;11:137. doi: 10.1186/1479-5876-11-137. PMID: 3731854 Free PMC article.

The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases. Müller M, Agaimy A, Zenk J, Ettl T, Iro H, Hartmann A, Seliger B, Schwarz S. Histopathology. 2013 May;62(6):847-59. doi: 10.1111/his.12086. PMID: 3611358

Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. Stehle F, Schulz K, Fahldieck C, Kalich J, Lichtenfels R, Riemann D, Seliger B. J Biol Chem. 2013 Jun 7;288(23):16334-47. doi: 10.1074/jbc.M112.437962. Epub 2013 Apr 26. PMID: 23625925 Free PMC article.

Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities. Massa C, Seliger B. J Immunol. 2013 Apr 1;190(7):3328-37. doi: 10.4049/jimmunol.1202024. Epub 2013 Feb 27. PMID: 23447683

Predictive immunomonitoring -- the COST ENTIRE initiative. Popadic D, Anegon I, Baeten D, Eibel H, Giese T, Marits P, Martinez-Caceres E, Mascart F, Nestle F, Pujol-Borrell R, Savic E, Scheibenbogen C, Seliger B, Thunberg S, Turina M, Villanova F, Winqvist O, Wikström AC. Clin Immunol. 2013 Apr;147(1):23-26. doi: 10.1016/j.clim.2013.01.013. Epub 2013 Feb 8. PMID: 23454893

The non-classical antigens of HLA-G and HLA-E as diagnostic and prognostic biomarkers and as therapeutic targets in transplantation and tumors.Seliger B. Clin Transpl. 2013:465-72. PMID: 25095542 Review.

Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes. Stoehr CG, Buettner-Herold M, Kamphausen E, Bertz S, Hartmann A, Seliger B. Int J Clin Exp Pathol. 2013 May 15;6(6):998-1008. Print 2013. PMID: 23696916 Free PMC article.

"Tumor Immunology Meets Oncology (TIMO) VIII" from May 4 to 5, 2012, in Halle/Saale, Germany. Barthel D, Seliger B. Cancer Immunol Immunother. 2013 Jan;62(1):197-202. doi: 10.1007/s00262-012-1374-6. Epub 2012 Nov 21. PMID: 23180013

"Tumor Immunology Meets Oncology (TIMO) VIII" from May 4 to 5, 2012, in Halle/Saale, Germany. Barthel D, Seliger B. Cancer Immunol Immunother. 2013 Jan;62(1):197-202. doi: 10.1007/s00262-012-1374-6. Epub 2012 Nov 21. PMID: 23180013

Opposing consequences of signaling through EGF family members: Escape from CTLs could be a bait for NK cells. Kiessling R, Okita R, Mougiakakos D, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kono K. Oncoimmunology. 2012 Oct 1;1(7):1200-1201. doi: 10.4161/onci.20685. PMID: 23170279 Free PMC article.

The expression, function, and clinical relevance of B7 family members in cancer.Seliger B, Quandt D. Cancer Immunol Immunother. 2012 Aug;61(8):1327-41. doi: 10.1007/s00262-012-1293-6. Epub 2012 Jun 14. PMID: 22695874 Review.

HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties. Recktenwald CV, Leisz S, Steven A, Mimura K, Müller A, Wulfänger J, Kiessling R, Seliger B. J Biol Chem. 2012 Jul 13;287(29):24320-9. doi: 10.1074/jbc.M111.334425. Epub 2012 May 11. PMID: 22582394 Free PMC article.

Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Stölzel F, Hackmann K, Kuithan F, Mohr B, Füssel M, Oelschlägel U, Thiede C, Röllig C, Platzbecker U, Schetelig J, Illmer T, Schaich M, Seliger B, Hartmann A, Baretton G, Zietz C, Ehninger G, Schrock E, Bornhäuser M. Transplantation. 2012 Apr 15;93(7):744-9. doi: 10.1097/TP.0b013e3182481113. PMID: 22314337

The role of classical and non-classical HLA class I antigens in human tumors. Bukur J, Jasinski S, Seliger B. Semin Cancer Biol. 2012 Aug;22(4):350-8. doi: 10.1016/j.semcancer.2012.03.003. Epub 2012 Mar 24. PMID: 22465194 Review.

Predominance of TH2 cells and plasma cells in polyoma virus nephropathy: a role for humoral immunity? Buettner M, Xu H, Böhme R, Seliger B, Jacobi J, Wiesener M, Benz K, Amann K. Hum Pathol. 2012 Sep;43(9):1453-62. doi: 10.1016/j.humpath.2011.11.006. Epub 2012 Mar 8. PMID: 22406372

Promoter methylation of aminopeptidase N/CD13 in malignant melanoma. Wulfänger J, Schneider H, Wild P, Ikenberg K, Rodolfo M, Rivoltini L, Meyer S, Riemann D, Seliger B. Carcinogenesis. 2012 Apr;33(4):781-90. doi: 10.1093/carcin/bgs091. Epub 2012 Feb 3. PMID: 22307972

HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kiessling R. J Immunol. 2012 Mar 1;188(5):2136-45. doi: 10.4049/jimmunol.1102237. Epub 2012 Feb 1. PMID: 22301547

Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV. Cancer Immunol Immunother. 2012 Aug;61(8):1243-53. doi: 10.1007/s00262-012-1201-0. Epub 2012 Jan 19. PMID: 22258792

Comparative expression profiling of distinct T cell subsets undergoing oxidative stress. Lichtenfels R, Mougiakakos D, Johansson CC, Dressler SP, Recktenwald CV, Kiessling R, Seliger B. PLoS One. 2012;7(7):e41345. doi: 10.1371/journal.pone.0041345. Epub 2012 Jul 20. PMID: 22911781 Free PMC article.

A proteomic view at T cell costimulation. Lichtenfels R, Rappl G, Hombach AA, Recktenwald CV, Dressler SP, Abken H, Seliger B. PLoS One. 2012;7(4):e32994. doi: 10.1371/journal.pone.0032994. Epub 2012 Apr 23. PMID: 22539942 Free PMC article.

Defining the critical hurdles in cancer immunotherapy. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214. PMID: 22168571 Free PMC article.

Novel insights into the molecular mechanisms of HLA class I abnormalities.Seliger B. Cancer Immunol Immunother. 2012 Feb;61(2):249-254. doi: 10.1007/s00262-011-1153-9. Epub 2011 Nov 27. PMID: 22120755 Review.

The immunomodulatory capacity of mesenchymal stem cells. Gebler A, Zabel O, Seliger B. Trends Mol Med. 2012 Feb;18(2):128-34. doi: 10.1016/j.molmed.2011.10.004. Epub 2011 Nov 25. PMID: 22118960 Review.

Methylation-specific ligation detection reaction (msLDR): a new approach for multiplex evaluation of methylation patterns. Bormann F, Sers C, Seliger B, Handke D, Bergmann T, Seibt S, Lehrach H, Dahl A. Mol Genet Genomics. 2011 Oct;286(3-4):279-91. doi: 10.1007/s00438-011-0645-9. Epub 2011 Aug 31. PMID: 21879293

Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.Seliger B, Dressler SP, Massa C, Recktenwald CV, Altenberend F, Bukur J, Marincola FM, Wang E, Stevanovic S, Lichtenfels R.

Proteomics. 2011 Jun;11(12):2528-41. doi: 10.1002/pmic.201000486. Epub 2011 May 18. PMID: 21595034 Free PMC article.

Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. Singer K, Kastenberger M, Gottfried E, Hammerschmied CG, Büttner M, Aigner M, Seliger B, Walter B, Schlösser H, Hartmann A, Andreesen R, Mackensen A, Kreutz M. Int J Cancer. 2011 May 1;128(9):2085-95. doi: 10.1002/ijc.25543. PMID: 20607826

Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation.

Rappl G, Pabst S, Riemann D, Schmidt A, Wickenhauser C, Schütte W, Hombach AA, Seliger B, Grohé C, Abken H. Clin Immunol. 2011 Jul;140(1):71-83. doi: 10.1016/j.clim.2011.03.015. Epub 2011 Mar 24. PMID: 21482483

B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Quandt D, Fiedler E, Boettcher D, Marsch WCh, Seliger B. Clin Cancer Res. 2011 May 15;17(10):3100-11. doi: 10.1158/1078-0432.CCR-10-2268. Epub 2011 Mar 4. PMID: 21378130

Monitoring peri-operative immune suppression in renal cancer patients. Hase S, Weinitschke K, Fischer K, Fornara P, Hoda R, Unverzagt S, Seliger B, Riemann D. Oncol Rep. 2011 May;25(5):1455-64. doi: 10.3892/or.2011.1199. Epub 2011 Mar 1. PMID: 21369703

Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Respa A, Bukur J, Ferrone S, Pawelec G, Zhao Y, Wang E, Marincola FM, Seliger B. Clin Cancer Res. 2011 May 1;17(9):2668-78. doi: 10.1158/1078-0432.CCR-10-2114. Epub 2011 Jan 19. PMID: 21248298 Free PMC article.

Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma?Seliger B, Jasinski S, Dressler SP, Marincola FM, Recktenwald CV, Wang E, Lichtenfels R. J Proteome Res. 2011 Jan 7;10(1):191-9. doi: 10.1021/pr1011137. PMID: 21142213 Free PMC article.

Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Amiot L, Ferrone S, Grosse-Wilde H, Seliger B. Cell Mol Life Sci. 2011 Feb;68(3):417-31. doi: 10.1007/s00018-010-0583-4. Epub 2010 Nov 10. PMID: 21063893 Free PMC article. Review.

Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system. Croci S, Recktenwald CV, Lichtenfels R, Nicoletti G, Dressler SP, De Giovanni C, Astolfi A, Palladini A, Shin-ya K, Landuzzi L, Nanni P, Lollini PL, Seliger B. Proteomics. 2010 Nov;10(21):3835-53. doi: 10.1002/pmic.200900643. PMID: 20957756

T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, Okita R, Nishimura MI, Handke D, Krug N, Choudhury A, Seliger B, Kiessling R. Int J Cancer. 2011 Jan 15;128(2):390-401. doi: 10.1002/ijc.25613. Epub 2010 Oct 13. PMID: 20715101

"Tumor immunology meets oncology (TIMO) VI" from 7th to 8th of May 2010 in Halle, Germany. Quandt D, Massa C, Seliger B. Cancer Immunol Immunother. 2011 Feb;60(2):299-303. doi: 10.1007/s00262-010-0912-3. Epub 2010 Aug 28. PMID: 20803010

Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B.

J Biol Chem. 2010 Oct 1;285(40):30419-26. doi: 10.1074/jbc.M109.094284. Epub 2010 Jul 27. PMID: 20663889 Free PMC article.

Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma. Kamphausen E, Kellert C, Abbas T, Akkad N, Tenzer S, Pawelec G, Schild H, van Endert P, Seliger B. Cancer Immunol Immunother. 2010 Aug;59(8):1273-84. doi: 10.1007/s00262-010-0856-7. Epub 2010 Apr 24. PMID: 20419298

Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.Seliger B, Massa C, Rini B, Ko J, Finke J. Trends Mol Med. 2010 Apr;16(4):184-92. doi: 10.1016/j.molmed.2010.02.001. Epub 2010 Mar 19. PMID: 20304705 Review.

Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A, Hofstaedter F, Hartmann A. Cancer Immunol Immunother. 2010 Apr;59(4):529-40. doi: 10.1007/s00262-009-0769-5. Epub 2009 Oct 7. PMID: 19820934 Free PMC article.

"Tumor immunology meets oncology IV", 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany. Bukur J, Loeffler D, Massa C, Mueller L, Riemann D, Schmoll HJ, Seliger B. Cancer Immunol Immunother. 2010 Jun;59(6):955-62. doi: 10.1007/s00262-008-0580-8. Epub 2008 Aug 28. PMID: 18751976

Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma.Seliger B, Handke D, Schabel E, Bukur J, Lichtenfels R, Dammann R.

J Transl Med. 2009 Oct 26;7:90. doi: 10.1186/1479-5876-7-90. PMID: 19857250 Free PMC article.

Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A, Hofstaedter F, Hartmann A. Cancer Immunol Immunother. 2010 Apr;59(4):529-40. doi: 10.1007/s00262-009-0769-5. Epub 2009 Oct 7. PMID: 19820934 Free PMC article.

Systematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by two-dimensional gel electrophoresis. Lichtenfels R, Dressler SP, Zobawa M, Recktenwald CV, Ackermann A, Atkins D, Kersten M, Hesse A, Puttkammer M, Lottspeich F, Seliger B. Mol Cell Proteomics. 2009 Dec;8(12):2827-42. doi: 10.1074/mcp.M900168-MCP200. Epub 2009 Sep 14. PMID: 19752005 Free PMC article.

Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma. Seliger B, Dressler SP, Wang E, Kellner R, Recktenwald CV, Lottspeich F, Marincola FM, Baumgärtner M, Atkins D, Lichtenfels R. Proteomics. 2009 Mar;9(6):1567-81. doi: 10.1002/pmic.200700288. PMID: 19235166 Free PMC article.

The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Helgadottir H, Andersson E, Villabona L, Kanter L, van der Zanden H, Haasnoot GW, Seliger B, Bergfeldt K, Hansson J, Ragnarsson-Olding B, Kiessling R, Masucci GV. Cancer Immunol Immunother. 2009 Oct;58(10):1599-608. doi: 10.1007/s00262-009-0669-8. Epub 2009 Feb 13. PMID: 19214504

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM. J Transl Med. 2008 Dec 23;6:81. doi: 10.1186/1479-5876-6-81. PMID: 19105846 Free PMC article.

CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells. Meissner M, Whiteside TL, Kaufmann R, Seliger B. Arch Dermatol Res. 2009 Feb;301(2):189-93. doi: 10.1007/s00403-008-0922-6. Epub 2008 Dec 23. PMID: 19104823

Altered detoxification status and increased resistance to oxidative stress by K-ras transformation. Recktenwald CV, Kellner R, Lichtenfels R, Seliger B. Cancer Res. 2008 Dec 15;68(24):10086-93. doi: 10.1158/0008-5472.CAN-08-0360. PMID: 19074874

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, Kiessling R, Blankenstein T, Abken H, Charo J. Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17481-6. doi: 10.1073/pnas.0804788105. Epub 2008 Nov 5. PMID: 18987320 Free PMC article.

The complex role of B7 molecules in tumor immunology.Seliger B, Marincola FM, Ferrone S, Abken H. Trends Mol Med. 2008 Dec;14(12):550-9. doi: 10.1016/j.molmed.2008.09.010. Epub 2008 Nov 3. PMID: 18986838 Free PMC article. Review.

Different regulation of MHC class I antigen processing components in human tumors.Seliger B. J Immunotoxicol. 2008 Oct;5(4):361-7. doi: 10.1080/15476910802482870. PMID: 19404870 Review.

HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Seliger B, Kiessling R. Cancer Immunol Immunother. 2009 May;58(5):653-64. doi: 10.1007/s00262-008-0587-1. Epub 2008 Sep 27. PMID: 18820911

"Tumor immunology meets oncology IV", 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany. Bukur J, Loeffler D, Massa C, Mueller L, Riemann D, Schmoll HJ, Seliger B. Cancer Immunol Immunother. 2010 Jun;59(6):955-62. doi: 10.1007/s00262-008-0580-8. Epub 2008 Aug 28. PMID: 18751976

Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Seliger B. Cancer Immunol Immunother. 2008 Nov;57(11):1719-26. doi: 10.1007/s00262-008-0515-4. Epub 2008 Apr 12. PMID: 18408926 Review.

IFN inducibility of major histocompatibility antigens in tumors.Seliger B, Ruiz-Cabello F, Garrido F. Adv Cancer Res. 2008;101:249-76. doi: 10.1016/S0065-230X(08)00407-7. PMID: 19055946 Free PMC article. Review.

Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion. Wulfaenger J, Niedling S, Riemann D, Seliger B. Mol Membr Biol. 2008 Jan;25(1):72-82. doi: 10.1080/09687680701551855. PMID: 18097955

Candidate biomarkers in renal cell carcinoma.Seliger B, Dressler SP, Lichtenfels R, Kellner R. Proteomics. 2007 Dec;7(24):4601-12. doi: 10.1002/pmic.200700415. PMID: 18072195 Review.

Structure, expression and function of HLA-G in renal cell carcinoma.Seliger B, Schlaf G. Semin Cancer Biol. 2007 Dec;17(6):444-50. doi: 10.1016/j.semcancer.2007.07.001. Epub 2007 Jul 13. PMID: 17707652 Review.

High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?

Altermann W, Schlaf G, Rothhoff A, Seliger B. Nephrol Dial Transplant. 2007 Oct;22(10):2795-9. doi: 10.1093/ndt/gfm397. Epub 2007 Jul 5. PMID: 17616534

Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues. Erhuma M, Köbel M, Mustafa T, Wulfänger J, Dralle H, Hoang-Vu C, Langner J, Seliger B, Kehlen A. Int J Cancer. 2007 Jun 1;120(11):2393-400. doi: 10.1002/ijc.22252. PMID: 17294442

Influence of Ki-ras-driven oncogenic transformation on the protein network of murine fibroblasts. Recktenwald CV, Mendler S, Lichtenfels R, Kellner R, Seliger B. Proteomics. 2007 Feb;7(3):385-98. doi: 10.1002/pmic.200600506.

PMID: 17211828

Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration.Seliger B, Fedorushchenko A, Brenner W, Ackermann A, Atkins D, Hanash S, Lichtenfels R. Clin Cancer Res. 2007 Jan 1;13(1):27-37. doi: 10.1158/1078-0432.CCR-06-0824. PMID: 17200335

Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1. Lou Y, Seipp RP, Cai B, Chen SS, Vitalis TZ, Choi KB, Jeffries AP, Gopaul RS, Li XL, Seliger B, Pearson TW, Jefferies WA. Vaccine. 2007 Mar 8;25(12):2331-9. doi: 10.1016/j.vaccine.2006.11.064. Epub 2006 Dec 12. PMID: 17229499

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B, Kiessling R. Cancer Res. 2006 Jun 15;66(12):6387-94. doi: 10.1158/0008-5472.CAN-06-0029. PMID: 16778217

Common cancer biomarkers. Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S, Mandruzzato S, Lee HM, Seliger B, Freedman RS, Taylor PR, Hu N, Zanovello P, Marincola FM, Wang E. Cancer Res. 2006 Mar 15;66(6):2953-61. doi: 10.1158/0008-5472.CAN-05-3433. PMID: 16540643

Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation.Seliger B, Ritz U, Ferrone S. Int J Cancer. 2006 Jan 1;118(1):129-38. doi: 10.1002/ijc.21312. PMID: 16003759 Review.

B7-1 and B7-2 act differentially in the induction of a T cell response: their impact for a HLA-matched and HLA-mismatched anti-tumor immunotherapy. Kronfeld K, Abken H, Seliger B. Int J Cancer. 2005 Dec 10;117(5):794-9. doi: 10.1002/ijc.21230. PMID: 15981208

Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Lou Y, Vitalis TZ, Basha G, Cai B, Chen SS, Choi KB, Jeffries AP, Elliott WM, Atkins D, Seliger B, Jefferies WA. Cancer Res. 2005 Sep 1;65(17):7926-33. doi: 10.1158/0008-5472.CAN-04-3977. PMID: 16140964

B7/CD28 costimulation of T cells induces a distinct proteome pattern. Kronfeld K, Hochleitner E, Mendler S, Goldschmidt J, Lichtenfels R, Lottspeich F, Abken H, Seliger B. Mol Cell Proteomics. 2005 Dec;4(12):1876-87. doi: 10.1074/mcp.M500194-MCP200. Epub 2005 Aug 19. PMID: 16113399

Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma.Seliger B, Lichtenfels R, Atkins D, Bukur J, Halder T, Kersten M, Harder A, Ackermann A, Malenica B, Brenner W, Zobawa M, Lottspeich F. Proteomics. 2005 Jul;5(10):2631-40. doi: 10.1002/pmic.200401264. PMID: 15892167

Identification and validation of novel ERBB2 (HER2, NEU) targets including genes involved in angiogenesis. Beckers J, Herrmann F, Rieger S, Drobyshev AL, Horsch M, Hrabé de Angelis M, Seliger B. Int J Cancer. 2005 Apr 20;114(4):590-7. doi: 10.1002/ijc.20798. PMID: 15609325

Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B. Clin Cancer Res. 2005 Apr 1;11(7):2552-60. doi: 10.1158/1078-0432.CCR-04-2146. PMID: 15814633

Strategies of tumor immune evasion.Seliger B. BioDrugs. 2005;19(6):347-54. doi: 10.2165/00063030-200519060-00002. PMID: 16392887 Review.

Heat shock proteins in renal cell carcinomas. Atkins D, Lichtenfels R, Seliger B. Contrib Nephrol. 2005;148:35-56. doi: 10.1159/000086042. PMID: 15912026 Review.

Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Wang E, Lichtenfels R, Bükur J, Ngalame Y, Panelli MC, Seliger B, Marincola FM. Cancer Res. 2004 Oct 15;64(20):7279-87. doi: 10.1158/0008-5472.CAN-04-1597. PMID: 15492247

Melanoma-restricted genes. Wang E, Panelli MC, Zavaglia K, Mandruzzato S, Hu N, Taylor PR, Seliger B, Zanovello P, Freedman RS, Marincola FM. J Transl Med. 2004 Oct 15;2(1):34. doi: 10.1186/1479-5876-2-34. PMID: 15488140

Regulation of beta1 integrin expression by PKCepsilon in renal cancer cells. Brenner W, Benzing F, Gudejko-Thiel J, Fischer R, Färber G, Hengstler JG, Seliger B, Thüroff JW. Int J Oncol. 2004 Oct;25(4):1157-63. PMID: 15375568

High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Meidenbauer N, Zippelius A, Pittet MJ, Laumer M, Vogl S, Heymann J, Rehli M, Seliger B, Schwarz S, Le Gal FA, Dietrich PY, Andreesen R, Romero P, Mackensen A. Cancer Res. 2004 Sep 1;64(17):6319-26. doi: 10.1158/0008-5472.CAN-04-1341. PMID: 15342421

Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas. Maleno I, Lopez Nevot MA, Seliger B, Garrido F. Int J Cancer. 2004 Apr 20;109(4):636-8. doi: 10.1002/ijc.20000. PMID: 14991587 Clinical Trial.

MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Störkel S, Seliger B. Int J Cancer. 2004 Mar 20;109(2):265-73. doi: 10.1002/ijc.11681. PMID: 14750179

CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Lindencrona JA, Preiss S, Kammertoens T, Schüler T, Piechocki M, Wei WZ, Seliger B, Blankenstein T, Kiessling R. Int J Cancer. 2004 Mar 20;109(2):259-64. doi: 10.1002/ijc.11654. PMID: 14750178

Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? Atkins D, Ferrone S, Schmahl GE, Störkel S, Seliger B. J Urol. 2004 Feb;171(2 Pt 1):885-9. doi: 10.1097/01.ju.0000094807.95420.fe. PMID: 14713847

HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, Seliger B. Cancer Res. 2004 Jan 1;64(1):215-20. doi: 10.1158/0008-5472.can-2522-2. PMID: 14729627

Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, Kiessling R. Int J Cancer. 2004 Jan 1;108(1):71-7. doi: 10.1002/ijc.11497. PMID: 14618618

Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Schiffer IB, Gebhard S, Heimerdinger CK, Heling A, Hast J, Wollscheid U, Seliger B, Tanner B, Gilbert S, Beckers T, Baasner S, Brenner W, Spangenberg C, Prawitt D, Trost T, Schreiber WG, Zabel B, Thelen M, Lehr HA, Oesch F, Hengstler JG. Cancer Res. 2003 Nov 1;63(21):7221-31. PMID: 14612517

Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Bukur J, Malenica B, Huber C, Seliger B. Hum Immunol. 2003 Nov;64(11):1081-92. doi: 10.1016/j.humimm.2003.08.350. PMID: 14602239

Detection of renal cell carcinoma-associated markers via proteome- and other 'ome'-based analyses.Seliger B, Lichtenfels R, Kellner R. Brief Funct Genomic Proteomic. 2003 Oct;2(3):194-212. doi: 10.1093/bfgp/2.3.194. PMID: 15239923

The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies. Bukur J, Seliger B. Semin Cancer Biol. 2003 Oct;13(5):353-9. doi: 10.1016/s1044-579x(03)00026-9. PMID: 14708715

Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma. Hodson I, Bock M, Ritz U, Brenner W, Huber C, Seliger B. Int J Oncol. 2003 Oct;23(4):991-9. PMID: 12963978

Cloning and functional analyses of the mouse tapasin promoter. Herrmann F, Trowsdale J, Huber C, Seliger B. Immunogenetics. 2003 Sep;55(6):379-88. doi: 10.1007/s00251-003-0597-2. Epub 2003 Aug 26. PMID: 12942211

Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. Herzer K, Falk CS, Encke J, Eichhorst ST, Ulsenheimer A, Seliger B, Krammer PH. J Virol. 2003 Aug;77(15):8299-309. doi: 10.1128/jvi.77.15.8299-8309.2003. PMID: 12857899

Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, Sutter G, Huber C, Seliger B. Cancer Res. 2003 Jul 15;63(14):4107-11. PMID: 12874014

A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T. Cancer Res. 2003 Jul 15;63(14):4095-100. PMID: 12874012

Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy.Seliger B, Menig M, Lichtenfels R, Atkins D, Bukur J, Halder TM, Kersten M, Harder A, Ackermann A, Beck J, Muehlenweg B, Brenner W, Melchior S, Kellner R, Lottspeich F. Proteomics. 2003 Jun;3(6):979-90. doi: 10.1002/pmic.200300404. PMID: 12833523

Tumors as elusive targets of T-cell-based active immunotherapy. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Trends Immunol. 2003 Jun;24(6):335-42. doi: 10.1016/s1471-4906(03)00116-9. PMID: 12810110

Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation.Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, Störkel S. Clin Cancer Res. 2003 May;9(5):1721-7. PMID: 12738726

Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Lichtenfels R, Kellner R, Atkins D, Bukur J, Ackermann A, Beck J, Brenner W, Melchior S, Seliger B. Biochim Biophys Acta. 2003 Mar 21;1646(1-2):21-31. doi: 10.1016/s1570-9639(02)00547-2. PMID: 12637008

HLA-G and MIC expression in tumors and their role in anti-tumor immunity.Seliger B, Abken H, Ferrone S. Trends Immunol. 2003 Feb;24(2):82-7. doi: 10.1016/s1471-4906(02)00039-x. PMID: 12547505

Impaired transporter associated with antigen processing (TAP) function attributable to a single amino acid alteration in the peptide TAP subunit TAP1. Ritz U, Drexler I, Sutter D, Abele R, Huber C, Seliger B. J Immunol. 2003 Jan 15;170(2):941-6. doi: 10.4049/jimmunol.170.2.941. PMID: 12517960

Functional cysteine-less subunits of the transporter associated with antigen processing (TAP1 and TAP2) by de novo gene assembly. Heintke S, Chen M, Ritz U, Lankat-Buttgereit B, Koch J, Abele R, Seliger B, Tampé R. FEBS Lett. 2003 Jan 2;533(1-3):42-6. doi: 10.1016/s0014-5793(02)03746-8. PMID: 12505156

Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Kellner R, Lichtenfels R, Atkins D, Bukur J, Ackermann A, Beck J, Brenner W, Melchior S, Seliger B. Proteomics. 2002 Dec;2(12):1743-51. doi: 10.1002/1615-9861(200212)2:12<1743::AID-PROT1743>3.0.CO;2-U. PMID: 12469344

Design of proteome-based studies in combination with serology for the identification of biomarkers and novel targets.Seliger B, Kellner R. Proteomics. 2002 Dec;2(12):1641-51. doi: 10.1002/1615-9861(200212)2:12<1641::AID-PROT1641>3.0.CO;2-B. PMID: 12469333

5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B, Maio M. Clin Cancer Res. 2002 Aug;8(8):2690-5. PMID: 12171902

Longitudinal analysis of the T-cell receptor (TCR)-VA and -VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen. Höhn H, Neukirch C, Freitag K, Necker A, Hitzler W, Seliger B, Maeurer MJ. Clin Exp Immunol. 2002 Aug;129(2):309-17. doi: 10.1046/j.1365-2249.2002.01841.x. PMID: 12165088

Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides. Scheibenbogen C, Nagorsen D, Seliger B, Schmittel A, Letsch A, Bauer S, Max N, Bock M, Atkins D, Thiel E, Keilholz U.

Int J Cancer. 2002 May 20;99(3):403-8. doi: 10.1002/ijc.10328. PMID: 11992409 

Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Qin Z, Harders C, Cao X, Huber C, Blankenstein T, Seliger B. Cancer Res. 2002 May 15;62(10):2856-60. PMID: 12019164

Tuning tumor-specific T-cell activation: a matter of costimulation? Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B. Trends Immunol. 2002 May;23(5):240-5. doi: 10.1016/s1471-4906(02)02180-4. PMID: 12102744

Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Lichtenfels R, Kellner R, Bukur J, Beck J, Brenner W, Ackermann A, Seliger B. Proteomics. 2002 May;2(5):561-70. doi: 10.1002/1615- 861(200205)2:5<561::AID-PROT561>3.0.CO;2-K. PMID: 11987130

HLA class I antigen abnormalities and immune escape by malignant cells.Seliger B, Cabrera T, Garrido F, Ferrone S. Semin Cancer Biol. 2002 Feb;12(1):3-13. doi: 10.1006/scbi.2001.0404. PMID: 11926409

High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors.Seliger B, Bock M, Ritz U, Huber C. Int J Oncol. 2002 Feb;20(2):349-53. PMID: 11788900

Cellular immunity to the Her-2/neu protooncogene. Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K, Seliger B. Adv Cancer Res. 2002;85:101-44. doi: 10.1016/s0065-230x(02)85004-7. PMID: 12374283

Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.Seliger B, Ritz U, Abele R, Bock M, Tampé R, Sutter G, Drexler I, Huber C, Ferrone S.

Cancer Res. 2001 Dec 15;61(24):8647-50. PMID: 11751378

Bipartite regulation of different components of the MHC class I antigen-processing machinery during dendritic cell maturation. Li J, Schuler-Thurner B, Schuler G, Huber C, Seliger B. Int Immunol. 2001 Dec;13(12):1515-23. doi: 10.1093/intimm/13.12.1515. PMID: 11717192

Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H. J Immunol. 2001 Dec 1;167(11):6123-31. doi: 10.4049/jimmunol.167.11.6123. PMID: 11714771

Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B. Int J Oncol. 2001 Dec;19(6):1211-20. doi: 10.3892/ijo.19.6.1211. PMID: 11713591

Mapping and expression pattern analysis of key components of the major histocompatibility complex class I antigen processing and presentation pathway in a representative human renal cell carcinoma cell line. Lichtenfels R, Ackermann A, Kellner R, Seliger B. Electrophoresis. 2001 May;22(9):1801-9. doi: 10.1002/1522-2683(200105)22:9<1801::AID-ELPS1801>3.0.CO;2-I. PMID: 11425235

The transporter associated with antigen processing (TAP): structural integrity, expression, function, and its clinical relevance. Ritz U, Seliger B. Mol Med. 2001 Mar;7(3):149-58. PMID: 11471551

T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, Seliger B, Abken H. Cancer Res. 2001 Mar 1;61(5):1976-82. PMID: 11280755

Consequences of a modified putative substrate-activation site on catalysis by yeast pyruvate decarboxylase. Wang J, Golbik R, Seliger B, Spinka M, Tittmann K, Hübner G, Jordan F. Biochemistry. 2001 Feb 13;40(6):1755-63. doi: 10.1021/bi001003r. PMID: 11327837

Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Cancer Res. 2001 Feb 1;61(3):1095-9. PMID: 11221838

Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines.Seliger B, Schreiber K, Delp K, Meissner M, Hammers S, Reichert T, Pawlischko K, Tampé R, Huber C. Tissue Antigens. 2001 Jan;57(1):39-45. doi: 10.1034/j.1399-0039.2001.057001039.x. PMID: 11169257

Identification of sequences in the human peptide transporter subunit TAP1 required for transporter associated with antigen processing (TAP) function. Ritz U, Momburg F, Pircher HP, Strand D, Huber C, Seliger B. Int Immunol. 2001 Jan;13(1):31-41. doi: 10.1093/intimm/13.1.31. PMID: 11133832

Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin.Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Tissue Antigens. 2000 Oct;56(4):327-36. doi: 10.1034/j.1399-0039.2000.560404.x. PMID: 11098932

Antigen-processing machinery breakdown and tumor growth.Seliger B, Maeurer MJ, Ferrone S. Immunol Today. 2000 Sep;21(9):455-64. doi: 10.1016/s0167-5699(00)01692-3. PMID: 10953098

HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.Seliger B, Rongcun Y, Atkins D, Hammers S, Huber C, Störkel S, Kiessling R. Int J Cancer. 2000 Aug 1;87(3):349-59. PMID: 10897039

Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin. Delp K, Momburg F, Hilmes C, Huber C, Seliger B. Bone Marrow Transplant. 2000 May;25 Suppl 2:S88-95. doi: 10.1038/sj.bmt.1702363. PMID: 10933198

CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. Höhn H, Pilch H, Günzel S, Neukirch C, Hilmes C, Kaufmann A, Seliger B, Maeurer MJ. J Immunol. 1999 Nov 15;163(10):5715-22. PMID: 10553103

Interleukin-15 in mycobacterial infection of antigen-presenting cells. Maeurer M, Seliger B, Trinder P, Gerdes J, Seitzer U. Scand J Immunol. 1999 Sep;50(3):280-8. doi: 10.1046/j.1365-3083.1999.00593.x. PMID: 10447937

Gene transfer of the Co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B. Scand J Immunol. 1999 Sep;50(3):242-9. doi: 10.1046/j.1365-3083.1999.00588.x. PMID: 10447932

Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A. Jäger E, Höhn H, Karbach J, Momburg F, Castelli C, Knuth A, Seliger B, Maeurer MJ. Int J Cancer. 1999 Jun 11;81(6):979-84. doi: 10.1002/(sici)1097-0215(19990611)81:6<979::aid-ijc22>3.0.co;2-y. PMID: 10362148

Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer. Kallfelz M, Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B. Int J Cancer. 1999 Mar 31;81(1):125-33. doi: 10.1002/(sici)1097-0215(19990331)81:1<125::aid-ijc21>3.0.co;2-2. PMID: 10077163

Constitutive and IFN-gamma regulated expression of IL-7 and IL-15 in human renal cell cancer. Trinder P, Seitzer U, Gerdes J, Seliger B, Maeurer M. Int J Oncol. 1999 Jan;14(1):23-31. doi: 10.3892/ijo.14.1.23. PMID: 9863005

Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M. J Immunol. 1998 Dec 1;161(11):6338-46. PMID: 9834124

Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Neumann E, Engelsberg A, Decker J, Störkel S, Jaeger E, Huber C, Seliger B. Cancer Res. 1998 Sep 15;58(18):4090-5. PMID: 9751617

Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. Wang Z, Seliger B, Mike N, Momburg F, Knuth A, Ferrone S. Cancer Res. 1998 May 15;58(10):2149-57. PMID: 9605759

Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies. Kishore R, Hicklin DJ, Dellaratta DV, Golde U, Kageshita T, Seliger B, Ferrone S. Tissue Antigens. 1998 Feb;51(2):129-40. doi: 10.1111/j.1399-0039.1998.tb02958.x. PMID: 9510369

Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.Seliger B, Harders C, Lohmann S, Momburg F, Urlinger S, Tampé R, Huber C. Eur J Immunol. 1998 Jan;28(1):122-33. doi: 10.1002/(SICI)1521-4141(199801)28:01<122::AID-IMMU122>3.0.CO;2-F. PMID: 9485192

Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes. Jung D, Jaeger E, Cayeux S, Blankenstein T, Hilmes C, Karbach J, Moebius U, Knuth A, Huber C, Seliger B. Hum Gene Ther. 1998 Jan 1;9(1):53-62. doi: 10.1089/hum.1998.9.1-53. PMID: 9458242

Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma.Seliger B, Dunn T, Schwenzer A, Casper J, Huber C, Schmoll HJ. Scand J Immunol. 1997 Dec;46(6):625-32. doi: 10.1046/j.1365-3083.1997.d01-176.x. PMID: 9420627

Expression and function of the peptide transporters in escape variants of human renal cell carcinomas.Seliger B, Höhne A, Jung D, Kallfelz M, Knuth A, Jaeger E, Bernhard H, Momburg F, Tampé R, Huber C. Exp Hematol. 1997 Jul;25(7):608-14. PMID: 9216736

TAP off--tumors on.Seliger B, Maeurer MJ, Ferrone S. Immunol Today. 1997 Jun;18(6):292-9. doi: 10.1016/s0167-5699(97)01052-9. PMID: 9190116

IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma.Seliger B, Hammers S, Höhne A, Zeidler R, Knuth A, Gerharz CD, Huber C. Clin Cancer Res. 1997 Apr;3(4):573-8. PMID: 9815722

Analysis of the p53 and MDM-2 gene in acute myeloid leukemia.Seliger B, Papadileris S, Vogel D, Hess G, Brendel C, Störkel S, Ortel J, Kolbe K, Huber C, Huhn D, Neubauer A. Eur J Haematol. 1996 Sep;57(3):230-40. doi: 10.1111/j.1600-0609.1996.tb01369.x. PMID: 8898928

Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.Seliger B, Harders C, Wollscheid U, Staege MS, Reske-Kunz AB, Huber C. Exp Hematol. 1996 Sep;24(11):1275-9. PMID: 8862437

Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma. Bernhard H, Maeurer MJ, Jäger E, Wölfel T, Schneider J, Karbach J, Seliger B, Huber C, Storkus WS, Lotze MT, Meyer zum Büschenfelde KH, Knuth A. Scand J Immunol. 1996 Sep;44(3):285-92. doi: 10.1046/j.1365-3083.1996.d01-304.x. PMID: 8795723

Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression.Seliger B, Höhne A, Knuth A, Bernhard H, Ehring B, Tampé R, Huber C. Clin Cancer Res. 1996 Aug;2(8):1427-33. PMID: 9816317

Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH. Decker HJ, Neuhaus C, Jauch A, Speicher M, Ried T, Bujard M, Brauch H, Störkel S, Stöckle M, Seliger B, Huber C. Hum Genet. 1996 Jun;97(6):770-6. doi: 10.1007/BF02346188. PMID: 8641695

Multiple levels of MHC class I down-regulation by ras oncogenes. Lohmann S, Wollscheid U, Huber C, Seliger B. Scand J Immunol. 1996 May;43(5):537-44. doi: 10.1046/j.1365-3083.1996.d01-73.x. PMID: 8633212

Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.Seliger B, Hohne A, Knuth A, Bernhard H, Meyer T, Tampe R, Momburg F, Huber C. Cancer Res. 1996 Apr 15;56(8):1756-60. PMID: 8620489

Partial restoration of pre-transformation levels of lysyl oxidase and transin mRNAs in phenotypic ras revertants. Oberhuber H, Seliger B, Schäfer R. Mol Carcinog. 1995 Apr;12(4):198-204. doi: 10.1002/mc.2940120404. PMID: 7727041

Induction of platelet-derived growth factor B/c-sis by the v-erbA oncogene in glial cells. Iglesias T, Llanos S, López-Barahona M, Seliger B, Rodríguez-Peña A, Bernal J, Muñoz A. Oncogene. 1995 Mar 16;10(6):1103-10. PMID: 7700635

Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. Bernhard H, Karbach J, Wölfel T, Busch P, Störkel S, Stöckle M, Wölfel C, Seliger B, Huber C, Meyer zum Büschenfelde KH, et al. Int J Cancer. 1994 Dec 15;59(6):837-42. doi: 10.1002/ijc.2910590621. PMID: 7989126

Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Hess G, Rose P, Gamm H, Papadileris S, Huber C, Seliger B. Br J Haematol. 1994 Dec;88(4):794-802. doi: 10.1111/j.1365-2141.1994.tb05119.x. PMID: 781910

c-erbA and v-erbA modulate growth and gene expression of a mouse glial precursor cell line. Iglesias T, Llanos S, López-Barahona M, Pérez-Aranda A, Rodríguez-Peña A, Bernal J, Höhne A, Seliger B, Muñoz A. Cell Growth Differ. 1994 Jul;5(7):697-704. PMID: 7947384

Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH, Boon T. Eur J Immunol. 1994 Mar;24(3):759-64. doi: 10.1002/eji.1830240340. PMID: 8125142

Molecular biology in hematology/oncology. Seliger B, Huber C. Internist (Berl). 1994 Feb;35(2):130-8. PMID: 8150578

7-Hydroxycoumarin inhibits oncogene-induced transformation of murine fibroblasts. Seliger B, Pettersson H. J Cancer Res Clin Oncol. 1994;120 Suppl:S23-7. doi: 10.1007/BF01377119. PMID: 8132698

Oncogene transformation can induce tolerogenicity in murine macrophages after down-regulation of immunogenicity without altering major histocompatibility complex antigen expression. Wottge HU, Eckstein V, Seliger B, Müller-Ruchholtz W. Scand J Immunol. 1993 Jul;38(1):49-56. doi: 10.1111/j.1365-3083.1993.tb01693.x. PMID: 8327859

Thyroid hormone receptor/c-erbA: control of commitment and differentiation in the neuronal/chromaffin progenitor line PC12. Muñoz A, Wrighton C, Seliger B, Bernal J, Beug H. J Cell Biol. 1993 Apr;121(2):423-38. doi: 10.1083/jcb.121.2.423. PMID: 8385673

Influence of oncogenes and cell metabolism on immunogenicity and tolerogenicity of a model macrophage cell line. Wottge HU, Seliger B, Eckstein V, Müller-Ruchholtz W. Transplant Proc. 1993 Feb;25(1 Pt 1):152-3. PMID: 8438258

Short-term treatment with gamma interferon induces stable reversion of ras-transformed mouse fibroblasts. Seliger B, Pfizenmaier K, Schäfer R. J Virol. 1991 Nov;65(11):6307-11. doi: 10.1128/JVI.65.11.6307-6311.1991. PMID: 1717721

Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Cancer Res. 1991 Apr 15;51(8):2164-72. PMID: 2009534

Cytokine-induced delivery of the costimulatory signal for a v-mos-transfected nonallostimulating, MHC I+II+ clone of the murine macrophage cell line P388D1 and induction of tolerance. Müller-Ruchholtz W, Seliger B, Eckstein V, Wottge HU. Transplant Proc. 1991 Feb;23(1 Pt 1):226-8. PMID: 1824978

Immunological properties of the murine macrophage cell line P388D1 and its oncogene transfectants in the induction of alloresponses. Wottge HU, Seliger B, Müller-Ruchholtz W. Transplant Proc. 1990 Aug;22(4):1994. PMID: 2143870

Gene transfer into brain tumor cell lines: reporter gene expression using various cellular and viral promoters. Oellig C, Seliger B. J Neurosci Res. 1990 Jul;26(3):390-6. doi: 10.1002/jnr.490260317. PMID: 2398515

Post-transcriptional downregulation of MHC class I expression in oncogene-transformed cells is reverted by IFN-gamma and TNF-alpha. Seliger B, Pfizenmaier K. J Immunogenet. 1989 Aug-Oct;16(4-5):315-20. doi: 10.1111/j.1744-313x.1989.tb00477.x. PMID: 2517949

Multiple injuries in children. Seliger B, Frowein RA. Neurosurg Rev. 1989;12 Suppl 1:59-62. doi: 10.1007/BF01790626. PMID: 2812436

Distinct mechanisms of interferon-gamma and tumor necrosis factor-alpha action in oncogene-transformed mouse fibroblasts. Seliger B, Killian M, Pfizenmaier K. J Cell Biochem. 1988 Nov;38(3):205-12. doi: 10.1002/jcb.240380308. PMID: 3147985

Tumor necrosis factor-alpha affects LTR-controlled oncogene expression in transformed mouse fibroblasts at the post-transcriptional level. Seliger B, Stark G, Pfizenmaier K. J Immunol. 1988 Sep 15;141(6):2138-44. PMID: 2844896

Gamma interferon regulates long terminal repeat-controlled oncogene expression in transformed mouse fibroblasts at the level of mRNA transcription. Seliger B, Kruppa G, Schäfer R, Redmond SM, Pfizenmaier K. J Virol. 1988 Feb;62(2):619-21. doi: 10.1128/JVI.62.2.619-621.1988. PMID: 3121865

Murine gamma interferon inhibits v-mos-induced fibroblast transformation via down regulation of retroviral gene expression. Seliger B, Kruppa G, Pfizenmaier K. J Virol. 1987 Aug;61(8):2567-72. doi: 10.1128/JVI.61.8.2567-2572.1987. PMID: 3037117

Stable expression of a selectable myeloproliferative sarcoma virus in murine T lymphocyte and monocyte cell lines.Seliger B, Kruppa G, Pfizenmaier K. Immunobiology. 1987 May;174(3):313-25. doi: 10.1016/S0171-2985(87)80006-2. PMID: 3040583

The myeloproliferative sarcoma virus retains transforming functions after introduction of a dominant selectable marker gene. Ostertag W, Seliger B, Kollek R, Stocking C, Bergholz U, Smadja-Joffe F. J Gen Virol. 1986 Jul;67 (Pt 7):1361-71. doi: 10.1099/0022-1317-67-7-1361. PMID: 3014049

Retroviral mutants efficiently expressed in embryonal carcinoma cells. Franz T, Hilberg F, Seliger B, Stocking C, Ostertag W. Proc Natl Acad Sci U S A. 1986 May;83(10):3292-6. doi: 10.1073/pnas.83.10.3292. PMID: 3010288

Viral transfer, transcription, and rescue of a selectable myeloproliferative sarcoma virus in embryonal cell lines: expression of the mos oncogene. Seliger B, Kollek R, Stocking C, Franz T, Ostertag W. Mol Cell Biol. 1986 Jan;6(1):286-93. doi: 10.1128/mcb.6.1.286. PMID: 3023829

Differential gamma-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effects of gamma-interferon on tumor cell growth. Pfizenmaier K, Bartsch H, Scheurich P, Seliger B, Ucer U, Vehmeyer K, Nagel GA. Cancer Res. 1985 Aug;45(8):3503-9. PMID: 3160456